042654695	042654695	CD	B-NP	O
|	|	NNP	I-NP	O
ENMCO	ENMCO	NNP	I-NP	O
|	|	VBD	B-VP	O
40356133	40356133	CD	B-NP	O
|	|	NN	I-NP	O
|	|	NN	I-NP	O
8425315	8425315	CD	B-NP	O
|	|	CC	I-NP	O
9/18/2004	9/18/2004	CD	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
AM	AM	VBP	B-VP	O
|	|	JJ	B-NP	B-protein
RIGHT	RIGHT	NNP	I-NP	I-protein
FOOT	FOOT	NNP	I-NP	I-protein
ULCER	ULCER	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
Signed	Signed	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
DIS	DIS	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
Admission	Admission	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
10/5/2004	10/5/2004	CD	B-NP	O
Report	Report	NNP	I-NP	O
Status	Status	NNP	I-NP	O
:	:	:	O	O
Signed	Signed	NNP	B-NP	O
Discharge	Discharge	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
7/11/2004	7/11/2004	CD	B-NP	O
ATTENDING	ATTENDING	NN	I-NP	O
:	:	:	O	O
FREDRIC	FREDRIC	NNP	B-NP	O
HILARIO	HILARIO	NNP	I-NP	O
MALICK	MALICK	NNP	I-NP	O
MD	MD	NNP	I-NP	O
SERVICE	SERVICE	NNP	I-NP	O
:	:	:	O	O
Vascular	Vascular	NNP	B-NP	O
Surgery	Surgery	NNP	I-NP	O
Service	Service	NNP	I-NP	O
.	.	.	O	O

HISTORY	HISTORY	NN	B-NP	O
OF	OF	IN	B-PP	O
PRESENT	PRESENT	JJ	B-NP	O
ILLNESS	ILLNESS	NN	I-NP	O
:	:	:	O	O
This	This	DT	B-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
61-year-old	61-year-old	JJ	I-NP	O
female	female	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
complicated	complicated	JJ	I-NP	O
past	past	JJ	I-NP	O
medical	medical	JJ	I-NP	O
history	history	NN	I-NP	O
notable	notable	JJ	B-ADJP	O
for	for	IN	B-PP	O
CVA	CVA	NN	B-NP	B-protein
and	and	CC	I-NP	O
peripheral	peripheral	JJ	I-NP	O
vascular	vascular	JJ	I-NP	O
disease	disease	NN	I-NP	O
with	with	IN	B-PP	O
chronic	chronic	JJ	B-NP	O
nonhealing	nonhealing	JJ	I-NP	O
foot	foot	NN	I-NP	O
ulcers	ulcer	NNS	I-NP	O
.	.	.	O	O

Patient	Patient	NN	B-NP	O
was	be	VBD	B-VP	O
seen	see	VBN	I-VP	O
a	a	DT	B-NP	O
week	week	NN	I-NP	O
prior	prior	JJ	B-ADJP	O
to	to	TO	B-PP	O
her	her	PRP$	B-NP	O
current	current	JJ	I-NP	O
admission	admission	NN	I-NP	O
in	in	IN	B-PP	O
Vascular	Vascular	NNP	B-NP	O
Clinic	Clinic	NNP	I-NP	O
for	for	IN	B-PP	O
evaluation	evaluation	NN	B-NP	O
of	of	IN	B-PP	O
nonhealing	nonhealing	JJ	B-NP	O
ulcers	ulcer	NNS	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
right	right	JJ	I-NP	O
foot	foot	NN	I-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
subsequently	subsequently	RB	I-VP	O
scheduled	schedule	VBN	I-VP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
right	right	JJ	I-NP	O
lower	low	JJR	I-NP	O
extremity	extremity	NN	I-NP	O
angiogram	angiogram	NN	I-NP	O
with	with	IN	B-PP	O
subsequent	subsequent	JJ	B-NP	O
debridement	debridement	NN	I-NP	O
planned	plan	VBN	B-VP	O
shortly	shortly	RB	B-ADVP	O
thereafter	thereafter	RB	I-ADVP	O
.	.	.	O	O

Two	Two	CD	B-NP	O
days	day	NNS	I-NP	O
prior	prior	RB	B-ADVP	O
to	to	TO	B-PP	O
admission	admission	NN	B-NP	O
,	,	,	O	O
however	however	RB	B-ADVP	O
,	,	,	O	O
the	the	DT	B-NP	O
staff	staff	NN	I-NP	O
at	at	IN	B-PP	O
her	her	PRP$	B-NP	O
rehabilitation	rehabilitation	NN	I-NP	O
facility	facility	NN	I-NP	O
noted	note	VBD	B-VP	O
increasing	increase	VBG	B-NP	O
erythema	erythema	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
area	area	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
ulcer	ulcer	NN	I-NP	O
associated	associate	VBN	B-VP	O
with	with	IN	B-PP	O
increased	increase	VBN	B-NP	O
complaints	complaint	NNS	I-NP	O
of	of	IN	B-PP	O
pain	pain	NN	B-NP	O
from	from	IN	B-PP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
.	.	.	O	O

Patient	Patient	NN	B-NP	O
was	be	VBD	B-VP	O
subsequently	subsequently	RB	I-VP	O
referred	refer	VBN	I-VP	O
to	to	TO	B-PP	O
Alstead	Alstead	NNP	B-NP	O
Medical	Medical	NNP	I-NP	O
Emergency	Emergency	NNP	I-NP	O
Department	Department	NNP	I-NP	O
for	for	IN	B-PP	O
further	further	JJ	B-NP	O
evaluation	evaluation	NN	I-NP	O
and	and	CC	I-NP	O
management	management	NN	I-NP	O
on	on	IN	B-PP	O
10/5/2004	10/5/2004	CD	B-NP	O
.	.	.	O	O

PAST	PAST	NNP	B-NP	O
MEDICAL	MEDICAL	NNP	I-NP	O
HISTORY	HISTORY	NNP	I-NP	O
:	:	:	O	O
Coronary	Coronary	JJ	B-NP	O
artery	artery	NN	I-NP	O
disease	disease	NN	I-NP	O
status	status	NN	I-NP	O
post	post	NN	I-NP	O
stent	stent	JJ	I-NP	O
placement	placement	NN	I-NP	O
in	in	IN	B-PP	O
1995	1995	CD	B-NP	O
,	,	,	O	O
hypertension	hypertension	NN	B-NP	O
,	,	,	O	O
hypercholesterolemia	hypercholesterolemia	NN	B-NP	O
,	,	,	O	O
peripheral	peripheral	JJ	B-NP	O
vascular	vascular	JJ	I-NP	O
disease	disease	NN	I-NP	O
,	,	,	O	O
seizure	seizure	NN	B-NP	O
disorder	disorder	NN	I-NP	O
,	,	,	O	O
hypothyroidism	hypothyroidism	NN	B-NP	O
,	,	,	O	O
systemic	systemic	JJ	B-NP	O
lupus	lupus	NN	I-NP	O
erythematous	erythematous	JJ	B-ADJP	O
,	,	,	O	O
anemia	anemia	NN	B-NP	O
of	of	IN	B-PP	O
chronic	chronic	JJ	B-NP	O
disease	disease	NN	I-NP	O
,	,	,	O	O
history	history	NN	B-NP	O
of	of	IN	B-PP	O
stroke	stroke	NN	B-NP	O
with	with	IN	B-PP	O
right-sided	right-sided	JJ	B-NP	O
hemiparesis	hemiparesis	NN	I-NP	O
since	since	IN	B-PP	O
1996	1996	CD	B-NP	O
,	,	,	O	O
and	and	CC	O	O
associated	associate	VBN	B-VP	O
high	high	JJ	B-NP	O
tone	tone	NN	I-NP	O
and	and	CC	O	O
spasticity	spasticity	NN	B-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
right	right	JJ	I-NP	O
lower	low	JJR	I-NP	O
extremity	extremity	NN	I-NP	O
,	,	,	O	O
history	history	NN	B-NP	O
of	of	IN	B-PP	O
subdural	subdural	JJ	B-NP	O
hematoma	hematoma	NN	I-NP	O
secondary	secondary	JJ	B-ADJP	O
to	to	TO	B-PP	O
a	a	DT	B-NP	O
fall	fall	NN	I-NP	O
,	,	,	O	O
migraines	migraine	NNS	B-NP	O
,	,	,	O	O
chronic	chronic	JJ	B-NP	O
pain	pain	NN	I-NP	O
syndrome	syndrome	NN	I-NP	O
,	,	,	O	O
narcotic	narcotic	JJ	B-NP	O
dependency	dependency	NN	I-NP	O
,	,	,	O	O
interstitial	interstitial	JJ	B-NP	O
lung	lung	NN	I-NP	O
disease	disease	NN	I-NP	O
secondary	secondary	JJ	B-ADJP	O
to	to	TO	B-PP	O
lupus	lupus	NN	B-NP	O
,	,	,	O	O
bipolar	bipolar	JJ	B-NP	O
disorder	disorder	NN	I-NP	O
,	,	,	O	O
chronic	chronic	JJ	B-NP	O
constipation	constipation	NN	I-NP	O
.	.	.	O	O

PAST	PAST	NN	B-NP	O
SURGICAL	SURGICAL	NN	I-NP	O
HISTORY	HISTORY	NN	I-NP	O
:	:	:	O	O
Right	Right	NN	B-NP	O
CEA	CEA	NN	I-NP	O
in	in	IN	B-PP	O
1999	1999	CD	B-NP	O
,	,	,	O	O
craniotomy	craniotomy	NN	B-NP	O
for	for	IN	B-PP	O
subdural	subdural	JJ	B-NP	O
hematoma	hematoma	NN	I-NP	O
in	in	IN	B-PP	O
1999	1999	CD	B-NP	O
.	.	.	O	O

HOME	HOME	NN	B-NP	O
MEDICATIONS	MEDICATIONS	NNS	I-NP	O
:	:	:	O	O
Premarin	Premarin	NN	B-NP	O
0.65	0.65	CD	I-NP	O
mg	mg	NN	I-NP	O
q.day	q.day	NN	I-NP	O
,	,	,	O	O
iron	iron	NN	B-NP	O
gluconate	gluconate	NN	I-NP	O
300	300	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.day	q.day	NN	I-NP	O
,	,	,	O	O
folate	folate	VB	B-VP	O
1	1	CD	B-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.day	q.day	NN	I-NP	O
,	,	,	O	O
multivitamin	multivitamin	NN	B-NP	O
p.o.	p.o.	NN	I-NP	O
q.day	q.day	NN	I-NP	O
,	,	,	O	O
Plaquenil	Plaquenil	NN	B-NP	O
200	200	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.day	q.day	NN	I-NP	O
,	,	,	O	O
Levoxyl	Levoxyl	NN	B-NP	O
200	200	CD	I-NP	O
mcg	mcg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.day	q.day	NN	I-NP	O
,	,	,	O	O
Toprol-XL	Toprol-XL	NN	B-NP	O
50	50	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.day	q.day	NN	I-NP	O
,	,	,	O	O
lisinopril	lisinopril	NN	B-NP	O
10	10	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.day	q.day	NN	I-NP	O
,	,	,	O	O
nicotine	nicotine	NN	B-NP	O
patch	patch	NN	I-NP	O
14	14	CD	I-NP	O
mcg	mcg	NN	I-NP	O
topical	topical	JJ	I-NP	O
,	,	,	I-NP	O
Celexa	Celexa	NNP	I-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.day	q.day	NN	I-NP	O
,	,	,	O	O
macrobid	macrobid	NN	B-NP	O
100	100	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
b.i.d.	b.i.d.	FW	I-ADVP	O
,	,	,	O	O
sodium	sodium	NN	B-NP	O
chloride	chloride	NN	I-NP	O
tablets	tablet	NNS	I-NP	O
,	,	,	O	O
hydralazine	hydralazine	NN	B-NP	O
10	10	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
t.i.d.	t.i.d.	FW	I-ADVP	O
,	,	,	O	O
Ultram	Ultram	NNP	B-NP	O
25	25	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.h.s.	q.h.s.	NN	I-NP	O
,	,	,	O	O
Neurontin	Neurontin	NN	B-NP	B-protein
100	100	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
p.o.	p.o.	FW	I-NP	I-protein
q.h.s.	q.h.s.	FW	I-NP	I-protein
Dilantin	Dilantin	NN	I-NP	I-protein
200	200	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
p.o.	p.o.	FW	I-NP	O
q.a.m.	q.a.m.	NN	I-NP	O
,	,	,	O	O
100	100	CD	B-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.afternoon	q.afternoon	NN	I-NP	O
,	,	,	O	O
200	200	CD	B-NP	O
p.o.	p.o.	NN	I-NP	O
q.p.m.	q.p.m.	NN	I-NP	O
Lipitor	Lipitor	NN	I-NP	O
10	10	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.day	q.day	NN	I-NP	O
,	,	,	O	O
Advair	Advair	NNP	B-NP	O
Diskus	Diskus	NNP	I-NP	O
500/50	500/50	CD	I-NP	O
1	1	CD	I-NP	O
puff	puff	NN	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
,	,	,	O	O
Colace	Colace	NNP	B-NP	O
100	100	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
b.i.d.	b.i.d.	FW	I-ADVP	O
,	,	,	O	O
Zyprexa	Zyprexa	NNP	B-NP	O
5	5	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.h.s.	q.h.s.	FW	I-NP	O
p.r.n.	p.r.n.	FW	I-NP	O
ALLERGIES	ALLERGIES	NNPS	I-NP	O
:	:	:	O	O
Sulfa	Sulfa	NNP	B-NP	O
.	.	.	O	O

Question	Question	NN	B-NP	O
of	of	IN	B-PP	O
allergy	allergy	NN	B-NP	O
to	to	TO	B-PP	O
Levaquin	Levaquin	NNP	B-NP	O
.	.	.	O	O

Questionable	Questionable	JJ	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
adverse	adverse	JJ	B-NP	O
reactions	reaction	NNS	I-NP	O
to	to	TO	B-PP	O
Prozac	Prozac	NN	B-NP	O
,	,	,	O	O
trazodone	trazodone	NN	B-NP	O
,	,	,	O	O
baclofen	baclofen	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
narcotics	narcotic	NNS	B-NP	O
.	.	.	O	O

SOCIAL	SOCIAL	JJ	B-NP	O
HISTORY	HISTORY	NN	I-NP	O
:	:	:	O	O
Patient	Patient	NN	B-NP	O
previously	previously	RB	B-VP	O
lived	live	VBN	I-VP	O
with	with	IN	B-PP	O
husband	husband	NN	B-NP	O
.	.	.	O	O

Patient	Patient	NN	B-NP	O
has	have	VBZ	B-VP	O
been	be	VBN	I-VP	O
wheelchair-dependent	wheelchair-dependent	JJ	B-ADJP	O
for	for	IN	B-PP	O
the	the	DT	B-NP	O
past	past	JJ	I-NP	O
four	four	CD	I-NP	O
weeks	week	NNS	I-NP	O
due	due	JJ	B-ADJP	O
to	to	TO	B-PP	O
her	her	PRP$	B-NP	O
chronic	chronic	JJ	I-NP	O
ulcers	ulcer	NNS	I-NP	O
.	.	.	O	O

Smokes	Smokes	NNP	B-NP	O
1-2	1-2	CD	I-NP	O
packs	pack	NNS	I-NP	O
per	per	IN	B-PP	O
day	day	NN	B-NP	O
until	until	IN	B-SBAR	O
approximately	approximately	RB	B-NP	O
four	four	CD	I-NP	O
weeks	week	NNS	I-NP	O
prior	prior	RB	B-ADVP	O
to	to	TO	B-PP	O
admission	admission	NN	B-NP	O
.	.	.	O	O

PHYSICAL	PHYSICAL	NN	B-NP	O
EXAMINATION	EXAMINATION	NN	I-NP	O
IN	IN	IN	B-PP	O
THE	THE	DT	B-NP	O
EMERGENCY	EMERGENCY	NN	I-NP	O
DEPARTMENT	DEPARTMENT	NN	I-NP	O
:	:	:	O	O
Afebrile	Afebrile	NN	B-NP	O
.	.	.	O	O

Heart	Heart	NN	B-NP	O
rate	rate	NN	I-NP	O
66	66	CD	I-NP	O
,	,	,	O	O
blood	blood	NN	B-NP	O
pressure	pressure	NN	I-NP	O
110/48	110/48	CD	I-NP	O
,	,	,	O	O
breathing	breathing	NN	B-NP	O
18	18	CD	I-NP	O
,	,	,	O	O
satting	satte	VBG	B-VP	O
98	98	CD	B-NP	O
%	%	NN	I-NP	O
on	on	IN	B-PP	O
room	room	NN	B-NP	O
air	air	NN	I-NP	O
.	.	.	O	O

Patient	Patient	NN	B-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
in	in	IN	B-PP	O
moderate	moderate	JJ	B-NP	O
distress	distress	NN	I-NP	O
secondary	secondary	JJ	B-ADJP	O
to	to	TO	B-VP	O
discomfort	discomfort	VB	I-VP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
right	right	JJ	I-NP	O
lower	low	JJR	I-NP	O
extremity	extremity	NN	I-NP	O
with	with	IN	B-PP	O
associated	associate	VBN	B-NP	O
spasm	spasm	NN	I-NP	O
and	and	CC	I-NP	O
foot	foot	NN	I-NP	O
pain	pain	NN	I-NP	O
.	.	.	O	O

Patient	Patient	NNP	B-NP	O
's	's	POS	B-NP	O
lungs	lung	NNS	I-NP	O
were	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
clear	clear	JJ	B-ADJP	O
to	to	TO	B-PP	O
auscultation	auscultation	NN	B-NP	O
bilaterally	bilaterally	RB	B-ADVP	O
.	.	.	O	O

A	A	DT	B-NP	O
well-healed	well-healed	JJ	I-NP	O
right	right	JJ	I-NP	O
CEA	CEA	NN	I-NP	O
scar	scar	NN	I-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
neck	neck	NN	I-NP	O
.	.	.	O	O

Patient	Patient	NN	B-NP	O
's	's	POS	B-NP	O
heart	heart	NN	I-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
a	a	DT	B-NP	O
regular	regular	JJ	I-NP	O
rate	rate	NN	I-NP	O
and	and	CC	O	O
rhythm	rhythm	NN	B-NP	O
with	with	IN	B-PP	O
no	no	DT	B-NP	O
murmurs	murmur	NNS	I-NP	O
,	,	,	I-NP	O
rubs	rub	NNS	I-NP	O
or	or	CC	I-NP	O
gallops	gallop	NNS	I-NP	O
.	.	.	O	O

Patient	Patient	NN	B-NP	O
's	's	POS	B-NP	O
abdomen	abdomen	NN	I-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
soft	soft	JJ	B-ADJP	O
,	,	,	I-ADJP	O
nondistended	nondistended	JJ	I-ADJP	O
and	and	CC	I-ADJP	O
nontender	nontender	JJ	I-ADJP	O
.	.	.	O	O

Extremity	Extremity	NN	B-NP	O
exam	exam	NN	I-NP	O
demonstrated	demonstrate	VBD	B-VP	O
a	a	DT	B-NP	O
right	right	JJ	I-NP	O
leg	leg	NN	I-NP	O
with	with	IN	B-PP	O
severe	severe	JJ	B-NP	O
knee	knee	NN	I-NP	O
contracture	contracture	NN	I-NP	O
and	and	CC	I-NP	O
spasm	spasm	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
left	left	JJ	I-NP	O
side	side	NN	I-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
normal	normal	JJ	B-ADJP	O
.	.	.	O	O

The	The	DT	B-NP	O
left	left	JJ	I-NP	O
foot	foot	NN	I-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
two	two	CD	B-NP	O
small	small	JJ	I-NP	O
clean	clean	JJ	I-NP	O
ulcers	ulcer	NNS	I-NP	O
,	,	,	O	O
one	one	CD	B-NP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
medial	medial	JJ	I-NP	O
bunion	bunion	NN	I-NP	O
and	and	CC	O	O
one	one	CD	B-NP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
tip	tip	NN	I-NP	B-protein
of	of	IN	B-PP	O
the	the	DT	B-NP	O
medial	medial	JJ	I-NP	O
great	great	JJ	I-NP	O
toe	toe	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
right	right	JJ	I-NP	O
foot	foot	NN	I-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
a	a	DT	B-NP	O
large	large	JJ	I-NP	O
dark	dark	JJ	I-NP	O
necrotic	necrotic	JJ	I-NP	O
pressure	pressure	NN	I-NP	O
wound	wound	NN	I-NP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
lateral	lateral	JJ	I-NP	O
aspect	aspect	NN	I-NP	O
and	and	CC	I-NP	O
plantar	plantar	NN	I-NP	O
aspect	aspect	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
mid	mid	JJ	I-NP	O
foot	foot	NN	I-NP	O
,	,	,	O	O
an	an	DT	B-NP	O
open	open	JJ	I-NP	B-DNA
infected-appearing	infected-appearing	JJ	I-NP	I-DNA
ulcer	ulcer	NN	I-NP	I-DNA
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
medial	medial	JJ	I-NP	O
forefoot	forefoot	NN	I-NP	O
with	with	IN	B-PP	O
surrounding	surround	VBG	B-VP	O
erythema	erythema	NN	B-NP	O
and	and	CC	O	O
a	a	DT	B-NP	O
greenish	greenish	JJ	I-NP	O
exudate	exudate	NN	I-NP	O
of	of	IN	B-PP	O
film	film	NN	B-NP	O
.	.	.	O	O

Pulse	Pulse	NN	B-NP	B-protein
exam	exam	NN	I-NP	I-protein
demonstrated	demonstrate	VBD	B-VP	I-protein
2	2	CD	B-NP	I-protein
+	+	SYM	I-NP	O
pulses	pulse	NNS	I-NP	O
in	in	IN	B-PP	O
bilateral	bilateral	JJ	B-NP	O
carotids	carotid	NNS	I-NP	O
,	,	,	O	O
radials	radial	NNS	B-NP	O
,	,	,	O	O
and	and	CC	O	O
femorals	femoral	NNS	B-NP	O
.	.	.	O	O

Right	Right	RB	B-NP	O
popliteal	popliteal	JJ	I-NP	O
biphasic	biphasic	JJ	I-NP	O
Doppler	Doppler	NNP	I-NP	O
pulses	pulse	NNS	I-NP	O
noted	note	VBD	B-VP	O
.	.	.	O	O

No	No	DT	B-NP	O
pulses	pulse	NNS	I-NP	O
were	be	VBD	B-VP	O
able	able	JJ	B-ADJP	O
to	to	TO	B-VP	O
be	be	VB	I-VP	O
distinguished	distinguish	VBN	I-VP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
right	right	JJ	I-NP	O
foot	foot	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
left	left	JJ	I-NP	O
foot	foot	NN	I-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
biphasic	biphasic	JJ	B-NP	O
signals	signal	NNS	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
DP	DP	NN	I-NP	O
and	and	CC	I-NP	O
PT	PT	NN	I-NP	O
by	by	IN	B-PP	O
Doppler	Doppler	NNP	B-NP	O
.	.	.	O	O

LABORATORY	LABORATORY	NN	B-NP	O
STUDIES	STUDIES	NNS	I-NP	O
UPON	UPON	NN	I-NP	O
ADMISSION	ADMISSION	NN	I-NP	O
:	:	:	O	O
Sodium	Sodium	NN	B-NP	O
136	136	CD	I-NP	O
,	,	,	O	O
potassium	potassium	NN	B-NP	O
4.8	4.8	CD	I-NP	O
,	,	,	O	O
chloride	chloride	NN	B-NP	O
101	101	CD	I-NP	O
,	,	,	O	O
bicarbonate	bicarbonate	NN	B-NP	O
23	23	CD	I-NP	O
,	,	,	O	O
BUN	BUN	NN	B-NP	B-DNA
21	21	CD	I-NP	I-DNA
,	,	,	O	O
creatinine	creatinine	NN	B-NP	O
1.1	1.1	CD	I-NP	O
,	,	,	O	O
glucose	glucose	NN	B-NP	O
74	74	CD	I-NP	O
.	.	.	O	O

ALT	ALT	NN	B-NP	O
was	be	VBD	B-VP	O
36	36	CD	B-NP	O
,	,	,	O	O
AST	AST	NN	B-NP	O
33	33	CD	I-NP	O
,	,	,	O	O
alk	alk	NN	B-NP	O
phos	pho	NNS	I-NP	O
173	173	CD	B-NP	O
,	,	,	O	O
total	total	JJ	B-NP	O
bili	bili	NNS	I-NP	O
0.3	0.3	CD	B-NP	O
,	,	,	O	O
albumin	albumin	NN	B-NP	O
4.0	4.0	CD	I-NP	O
.	.	.	O	O

White	White	JJ	B-NP	O
blood	blood	NN	I-NP	O
cell	cell	NN	I-NP	O
count	count	NN	I-NP	O
was	be	VBD	B-VP	O
9.6	9.6	CD	B-NP	O
,	,	,	O	O
hematocrit	hematocrit	NN	B-NP	B-protein
36.2	36.2	CD	I-NP	I-protein
,	,	,	O	O
and	and	CC	O	O
platelets	platelet	NNS	B-NP	B-cell_type
232	232	CD	B-NP	O
.	.	.	O	O

PT	PT	NN	B-NP	B-protein
13.4	13.4	CD	I-NP	I-protein
,	,	,	O	O
PTT	PTT	NN	B-NP	B-protein
28.1	28.1	CD	I-NP	I-protein
,	,	,	O	O
INR	INR	NN	B-NP	B-protein
1.0	1.0	CD	I-NP	I-protein
.	.	.	O	O

Chest	Ch	JJS	B-NP	O
x-ray	x-ray	NN	I-NP	B-DNA
demonstrated	demonstrate	VBD	B-VP	O
a	a	DT	B-NP	O
mild	mild	JJ	I-NP	O
interstitial	interstitial	JJ	I-NP	O
disease	disease	NN	I-NP	O
with	with	IN	B-PP	O
multiple	multiple	JJ	B-NP	O
old	old	JJ	I-NP	O
right	right	JJ	I-NP	O
rib	rib	NN	I-NP	O
fractures	fracture	NNS	I-NP	O
.	.	.	O	O

X-ray	X-ray	NN	B-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
feet	foot	NNS	I-NP	O
demonstrated	demonstrate	VBD	B-VP	O
bilateral	bilateral	JJ	B-NP	O
osteopenia	osteopenia	NN	I-NP	O
with	with	IN	B-PP	O
no	no	DT	B-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
osteomyelitis	osteomyelitis	NN	B-NP	O
in	in	IN	B-PP	O
either	either	DT	B-NP	O
foot	foot	NN	I-NP	O
.	.	.	O	O

EKG	EKG	NN	B-NP	B-protein
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
normal	normal	JJ	B-ADJP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
normal	normal	JJ	I-NP	O
sinus	sinus	NN	I-NP	O
rhythm	rhythm	NN	I-NP	O
at	at	IN	B-PP	O
63	63	CD	B-NP	O
.	.	.	O	O

HOSPITAL	HOSPITAL	JJ	B-NP	O
COURSE	COURSE	NN	I-NP	O
:	:	:	O	O
Patient	Patient	NN	B-NP	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
Vascular	Vascular	NNP	I-NP	O
Surgery	Surgery	NNP	I-NP	O
Service	Service	NNP	I-NP	O
on	on	IN	B-PP	O
10/5/2004	10/5/2004	CD	B-NP	O
for	for	IN	B-PP	O
further	further	JJ	B-NP	O
evaluation	evaluation	NN	I-NP	O
and	and	CC	I-NP	O
management	management	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
empirically	empirically	RB	I-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
vancomycin	vancomycin	NN	B-NP	O
and	and	CC	I-NP	O
ceftazidime	ceftazidime	NN	I-NP	O
with	with	IN	B-PP	O
wet-to-dry	wet-to-dry	JJ	B-NP	O
dressings	dressing	NNS	I-NP	O
applied	apply	VBN	B-VP	O
to	to	TO	B-PP	O
her	her	PRP$	B-NP	O
right	right	JJ	I-NP	O
foot	foot	NN	I-NP	O
wound	wound	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
also	also	RB	I-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
prior	prior	JJ	I-NP	O
dose	dose	NN	I-NP	O
of	of	IN	B-PP	O
Macrobid	Macrobid	NNP	B-NP	O
for	for	IN	B-PP	O
previously-diagnosed	previously-diagnosed	JJ	B-NP	O
UTI	UTI	NN	I-NP	O
with	with	IN	B-PP	O
her	her	PRP$	B-NP	O
antibiotic	antibiotic	JJ	I-NP	O
regimen	regimen	NN	I-NP	O
to	to	TO	B-VP	O
be	be	VB	I-VP	O
discontinued	discontinue	VBN	I-VP	O
for	for	IN	B-PP	O
this	this	DT	B-NP	O
purpose	purpose	NN	I-NP	O
on	on	IN	B-PP	O
9/8/2004	9/8/2004	CD	B-NP	O
.	.	.	O	O

An	An	DT	B-NP	O
angiogram	angiogram	NN	I-NP	O
performed	perform	VBN	B-VP	O
on	on	IN	B-PP	O
hospital	hospital	NN	B-NP	O
day	day	NN	I-NP	O
#	#	#	B-NP	O
2	2	CD	I-NP	O
,	,	,	O	O
revealed	reveal	VBD	B-VP	O
a	a	DT	B-NP	O
right	right	JJ	I-NP	O
external	external	JJ	I-NP	O
iliac	iliac	JJ	I-NP	O
occlusion	occlusion	NN	I-NP	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
stented	stente	VBN	I-VP	O
near	near	IN	B-PP	O
the	the	DT	B-NP	O
bifurcation	bifurcation	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
internal	internal	JJ	I-NP	O
and	and	CC	I-NP	O
external	external	JJ	I-NP	O
iliac	iliac	JJ	I-NP	O
vessels	vessel	NNS	I-NP	O
.	.	.	O	O

A	A	DT	B-NP	O
distal	distal	JJ	I-NP	O
stenosis	stenosis	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
external	external	JJ	I-NP	O
iliac	iliac	NN	I-NP	O
was	be	VBD	B-VP	O
opened	open	VBN	I-VP	O
with	with	IN	B-PP	O
balloon	balloon	NN	B-NP	O
angioplasty	angioplasty	JJ	B-ADJP	O
to	to	TO	B-PP	O
good	good	JJ	B-NP	O
effect	effect	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
sustained	sustain	VBD	B-VP	O
a	a	DT	B-NP	O
mild	mild	JJ	I-NP	O
groin	groin	NN	I-NP	O
hematoma	hematoma	NN	I-NP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
left	left	NN	I-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
access	access	NN	I-NP	O
site	site	NN	I-NP	O
but	but	CC	O	O
had	have	VBD	B-VP	O
no	no	DT	B-NP	O
change	change	NN	I-NP	O
in	in	IN	B-PP	O
her	her	PRP$	B-NP	O
pulse	pulse	NN	I-NP	O
exam	exam	NN	I-NP	O
there	there	EX	B-NP	O
afterwards	afterwards	RB	B-ADVP	O
.	.	.	O	O

Following	Follow	VBG	B-PP	O
her	her	PRP$	B-NP	O
angiogram	angiogram	NN	I-NP	O
and	and	CC	I-NP	O
percutaneous	percutaneous	JJ	I-NP	O
intervention	intervention	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
demonstrate	demonstrate	VB	I-VP	O
excellent	excellent	JJ	B-NP	O
right	right	RB	I-NP	O
lower	low	JJR	I-NP	O
extremity	extremity	NN	I-NP	O
DP	DP	NN	I-NP	O
and	and	CC	I-NP	O
PT	PT	NN	I-NP	O
pulses	pulse	NNS	I-NP	O
which	which	WDT	B-NP	O
remained	remain	VBD	B-VP	O
palpable	palpable	JJ	B-ADJP	O
through	through	IN	B-PP	O
the	the	DT	B-NP	O
duration	duration	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
hospital	hospital	NN	I-NP	O
course	course	NN	I-NP	O
.	.	.	O	O

On	On	IN	B-PP	O
hospital	hospital	NN	B-NP	O
day	day	NN	I-NP	O
#	#	#	B-NP	O
3	3	CD	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
brought	bring	VBN	I-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
operating	operating	NN	I-NP	O
room	room	NN	I-NP	O
for	for	IN	B-PP	O
debridement	debridement	NN	B-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
right	right	JJ	I-NP	O
foot	foot	NN	I-NP	O
.	.	.	O	O

For	For	IN	B-PP	O
a	a	DT	B-NP	O
detailed	detailed	JJ	I-NP	O
description	description	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
operative	operative	JJ	I-NP	O
procedure	procedure	NN	I-NP	O
,	,	,	O	O
please	please	VB	B-VP	O
the	the	DT	B-NP	O
relevant	relevant	JJ	I-NP	O
operative	operative	JJ	I-NP	O
note	note	NN	I-NP	O
.	.	.	O	O

Patient	Patient	NN	B-NP	O
tolerated	tolerate	VBD	B-VP	O
the	the	DT	B-NP	O
procedure	procedure	NN	I-NP	O
well	well	RB	B-ADVP	O
and	and	CC	O	O
during	during	IN	B-PP	O
the	the	DT	B-NP	O
procedure	procedure	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
ulcer	ulcer	NN	I-NP	O
base	base	NN	I-NP	O
was	be	VBD	B-VP	O
found	find	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
contiguous	contiguous	JJ	B-ADJP	O
with	with	IN	B-PP	O
the	the	DT	B-NP	O
first	first	JJ	I-NP	O
metatarsal	metatarsal	JJ	I-NP	O
head	head	NN	I-NP	O
periosteum	periosteum	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
therefore	therefore	RB	B-ADVP	O
,	,	,	O	O
a	a	DT	B-NP	O
metatarsal	metatarsal	JJ	I-NP	O
head	head	NN	I-NP	O
excision	excision	NN	I-NP	O
was	be	VBD	B-VP	O
performed	perform	VBN	I-VP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
great	great	JJ	I-NP	O
toe	toe	NN	I-NP	O
was	be	VBD	B-VP	O
left	leave	VBN	I-VP	O
in	in	IN	B-PP	O
place	place	NN	B-NP	O
with	with	IN	B-PP	O
moderate	moderate	JJ	B-NP	O
debridement	debridement	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
deep	deep	JJ	I-NP	O
tissues	tissue	NNS	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
ulcers	ulcer	NNS	I-NP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
lateral	lateral	JJ	I-NP	O
right	right	JJ	I-NP	O
foot	foot	NN	I-NP	O
were	be	VBD	B-VP	O
not	not	RB	I-VP	O
debrided	debride	VBN	I-VP	O
at	at	IN	B-PP	O
this	this	DT	B-NP	O
time	time	NN	I-NP	O
.	.	.	O	O

Following	Follow	VBG	B-PP	O
her	her	PRP$	B-NP	O
procedure	procedure	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
empirically	empirically	RB	I-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
vancomycin	vancomycin	NN	B-NP	O
and	and	CC	I-NP	O
ceftazidime	ceftazidime	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	B-cell_line
operative	operative	JJ	I-NP	I-cell_line
cultures	culture	NNS	I-NP	I-cell_line
subsequently	subsequently	RB	B-ADVP	O
grew	grow	VBD	B-VP	O
out	out	RP	B-PRT	O
coagulase-negative	coagulase-negative	JJ	B-NP	O
staph	staph	NN	I-NP	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
sensitive	sensitive	JJ	B-ADJP	O
to	to	TO	B-PP	O
both	both	CC	O	O
Keflex	Keflex	NNP	B-NP	O
and	and	CC	O	O
vancomycin	vancomycin	NN	B-NP	O
.	.	.	O	O

At	At	IN	B-PP	O
this	this	DT	B-NP	O
point	point	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
switched	switch	VBN	I-VP	O
to	to	TO	B-PP	O
vancomycin	vancomycin	NN	B-NP	O
therapy	therapy	NN	I-NP	O
only	only	RB	B-ADVP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
VAC	VAC	NN	B-NP	O
therapy	therapy	NN	I-NP	O
through	through	IN	B-PP	O
postoperative	postoperative	JJ	B-NP	B-protein
day	day	NN	I-NP	I-protein
#	#	#	B-NP	I-protein
3	3	CD	I-NP	I-protein
.	.	.	O	O

At	At	IN	B-PP	O
this	this	DT	B-NP	O
point	point	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
VAC	VAC	NN	I-NP	O
dressing	dressing	NN	I-NP	O
was	be	VBD	B-VP	O
changed	change	VBN	I-VP	O
to	to	TO	B-VP	O
demonstrate	demonstrate	VB	I-VP	O
a	a	DT	B-NP	O
well-vascularized	well-vascularized	JJ	I-NP	O
actively	actively	RB	I-NP	O
bleeding	bleed	VBG	I-NP	O
wound	wound	NN	B-NP	O
with	with	IN	B-PP	O
granulation	granulation	NN	B-NP	O
tissue	tissue	NN	I-NP	O
and	and	CC	O	O
no	no	DT	B-NP	O
signs	sign	NNS	I-NP	O
of	of	IN	B-PP	O
wound	wound	NN	B-NP	O
necrosis	necrosis	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
remained	remain	VBD	B-VP	O
in	in	IN	B-PP	O
stable	stable	JJ	B-NP	O
condition	condition	NN	I-NP	O
through	through	IN	B-PP	O
postoperative	postoperative	JJ	B-NP	O
day	day	NN	I-NP	O
#	#	#	B-NP	O
7	7	CD	I-NP	O
at	at	IN	B-PP	O
which	which	WDT	B-NP	O
point	point	NN	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
returned	return	VBN	I-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
operating	operating	NN	I-NP	O
room	room	NN	I-NP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
great	great	JJ	I-NP	O
toe	toe	NN	I-NP	O
amputation	amputation	NN	I-NP	O
and	and	CC	O	O
definitive	definitive	JJ	B-NP	O
closure	closure	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
right	right	JJ	I-NP	O
foot	foot	NN	I-NP	O
wound	wound	NN	I-NP	O
.	.	.	O	O

For	For	IN	B-PP	O
a	a	DT	B-NP	O
detailed	detailed	JJ	I-NP	O
description	description	NN	I-NP	O
of	of	IN	B-PP	O
this	this	DT	B-NP	O
operative	operative	JJ	I-NP	O
procedure	procedure	NN	I-NP	O
,	,	,	O	O
please	please	NN	B-NP	O
see	see	VBP	B-VP	O
the	the	DT	B-NP	O
relevant	relevant	JJ	I-NP	O
operative	operative	JJ	I-NP	O
note	note	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
tolerated	tolerate	VBD	B-VP	O
the	the	DT	B-NP	O
procedure	procedure	NN	I-NP	O
well	well	RB	B-ADVP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
subsequently	subsequently	RB	I-VP	O
returned	return	VBN	I-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
Regular	Regular	JJ	I-NP	O
Outpatient	Outpatient	NN	I-NP	O
Floor	Floor	NN	I-NP	O
where	where	WRB	B-ADVP	O
she	she	PRP	B-NP	O
remained	remain	VBD	B-VP	O
for	for	IN	B-PP	O
the	the	DT	B-NP	O
duration	duration	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
stay	stay	NN	I-NP	O
.	.	.	O	O

A	A	DT	B-NP	O
general	general	JJ	I-NP	O
overview	overview	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
hospital	hospital	NN	I-NP	O
course	course	NN	I-NP	O
by	by	IN	B-PP	O
system	system	NN	B-NP	O
is	be	VBZ	B-VP	O
as	as	IN	B-SBAR	O
follows	follow	VBZ	B-VP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Neurological	Neurological	JJ	B-ADJP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
demonstrated	demonstrate	VBD	B-VP	O
significant	significant	JJ	B-NP	O
issues	issue	NNS	I-NP	O
with	with	IN	B-PP	O
pain	pain	NN	B-NP	O
control	control	NN	I-NP	O
for	for	IN	B-PP	O
the	the	DT	B-NP	O
duration	duration	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
stay	stay	NN	I-NP	O
.	.	.	O	O

A	A	DT	B-NP	O
fair	fair	JJ	I-NP	O
amount	amount	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
pain	pain	NN	I-NP	O
was	be	VBD	B-VP	O
determined	determine	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
secondary	secondary	JJ	B-ADJP	O
to	to	TO	B-PP	O
her	her	PRP$	B-NP	O
right	right	JJ	I-NP	O
foot	foot	NN	I-NP	O
ulcer	ulcer	NN	I-NP	O
;	;	:	O	O
however	however	RB	B-ADVP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
also	also	RB	I-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
significant	significant	JJ	B-NP	O
pain	pain	NN	I-NP	O
associated	associate	VBN	B-VP	O
with	with	IN	B-PP	O
her	her	PRP$	B-NP	O
contracted	contract	VBD	B-VP	O
right	right	RB	B-NP	O
lower	low	JJR	I-NP	O
extremity	extremity	NN	I-NP	O
.	.	.	O	O

For	For	IN	B-PP	O
a	a	DT	B-NP	O
time	time	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
placed	place	VBN	I-VP	O
in	in	IN	B-PP	O
a	a	DT	B-NP	O
right	right	JJ	I-NP	O
lower	low	JJR	I-NP	O
extremity	extremity	NN	I-NP	O
extension	extension	NN	I-NP	O
brace	brace	NN	I-NP	O
which	which	WDT	B-NP	O
provided	provide	VBD	B-VP	O
some	some	DT	B-NP	O
measure	measure	NN	I-NP	O
of	of	IN	B-PP	O
relief	relief	NN	B-NP	O
;	;	:	O	O
however	however	RB	B-ADVP	O
,	,	,	O	O
upon	upon	IN	B-PP	O
regular	regular	JJ	B-NP	O
examination	examination	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
right	right	JJ	I-NP	O
lower	low	JJR	I-NP	O
extremity	extremity	NN	I-NP	O
,	,	,	O	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
that	that	IN	B-SBAR	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
gradually	gradually	RB	I-VP	O
developing	develop	VBG	I-VP	O
pressure	pressure	NN	B-NP	O
ulcers	ulcer	NNS	I-NP	O
secondary	secondary	JJ	B-ADJP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
extension	extension	NN	I-NP	O
brace	brace	NN	I-NP	O
.	.	.	O	O

A	A	DT	B-NP	O
Neurology	Neurology	NNP	I-NP	O
and	and	CC	I-NP	O
Pain	Pain	NNP	I-NP	O
Service	Service	NNP	I-NP	O
consultation	consultation	NN	I-NP	O
was	be	VBD	B-VP	O
obtained	obtain	VBN	I-VP	O
and	and	CC	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
subsequently	subsequently	RB	I-VP	O
recommended	recommend	VBN	I-VP	O
for	for	IN	B-PP	O
Zanaflex	Zanaflex	NN	B-NP	O
therapy	therapy	NN	I-NP	O
which	which	WDT	B-NP	O
subsequently	subsequently	RB	B-ADVP	O
improved	improve	VBD	B-VP	O
her	her	PRP$	B-NP	O
pain	pain	NN	I-NP	O
control	control	NN	I-NP	O
dramatically	dramatically	RB	B-ADVP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
otherwise	otherwise	RB	B-ADVP	O
remained	remain	VBD	B-VP	O
intact	intact	JJ	B-ADJP	O
from	from	IN	B-PP	O
a	a	DT	B-NP	O
neurological	neurological	JJ	I-NP	O
perspective	perspective	NN	I-NP	O
for	for	IN	B-PP	O
the	the	DT	B-NP	O
duration	duration	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
stay	stay	NN	I-NP	O
,	,	,	O	O
demonstrating	demonstrate	VBG	B-VP	O
frequent	frequent	JJ	B-NP	O
emotional	emotional	JJ	I-NP	O
ability	ability	NN	I-NP	O
consistent	consistent	JJ	B-ADJP	O
with	with	IN	B-PP	O
her	her	PRP$	B-NP	O
baseline	baseline	NN	I-NP	O
examination	examination	NN	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Cardiovascular	Cardiovascular	JJ	B-ADJP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
remained	remain	VBD	B-VP	O
stable	stable	JJ	B-ADJP	O
from	from	IN	B-PP	O
a	a	DT	B-NP	O
cardiovascular	cardiovascular	JJ	I-NP	O
perspective	perspective	NN	I-NP	O
for	for	IN	B-PP	O
the	the	DT	B-NP	O
duration	duration	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
stay	stay	NN	I-NP	O
with	with	IN	B-PP	O
no	no	DT	B-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
acute	acute	JJ	B-NP	O
hemodynamic	hemodynamic	JJ	I-NP	O
instability	instability	NN	I-NP	O
or	or	CC	I-NP	O
compromise	compromise	NN	I-NP	O
.	.	.	O	O

At	At	IN	B-PP	O
no	no	DT	B-NP	O
point	point	NN	I-NP	O
did	do	VBD	B-VP	O
she	she	PRP	B-NP	O
demonstrate	demonstrate	VBP	B-VP	O
evidence	evidence	NN	B-NP	O
of	of	IN	B-PP	O
acute	acute	JJ	B-NP	O
myocardial	myocardial	JJ	I-NP	O
ischemia	ischemia	NN	I-NP	O
or	or	CC	I-NP	O
infarction	infarction	NN	I-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Pulmonary	Pulmonary	JJ	B-ADJP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
remained	remain	VBD	B-VP	O
stable	stable	JJ	B-ADJP	O
from	from	IN	B-PP	O
a	a	DT	B-NP	O
pulmonary	pulmonary	JJ	I-NP	O
perspective	perspective	NN	I-NP	O
for	for	IN	B-PP	O
the	the	DT	B-NP	O
duration	duration	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
stay	stay	NN	I-NP	O
with	with	IN	B-PP	O
no	no	DT	B-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
acute	acute	JJ	B-NP	O
respiratory	respiratory	JJ	I-NP	O
decompensation	decompensation	NN	I-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

GI	GI	LS	B-LST	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
remained	remain	VBD	B-VP	O
stable	stable	JJ	B-ADJP	O
from	from	IN	B-PP	O
a	a	DT	B-NP	O
gastrointestinal	gastrointestinal	JJ	I-NP	O
standpoint	standpoint	NN	I-NP	O
for	for	IN	B-PP	O
the	the	DT	B-NP	O
duration	duration	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
stay	stay	NN	I-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
tolerant	tolerant	JJ	B-ADJP	O
of	of	IN	B-PP	O
both	both	CC	B-NP	O
solid	solid	JJ	I-NP	O
and	and	CC	I-NP	O
liquid	liquid	JJ	I-NP	O
oral	oral	JJ	I-NP	O
intake	intake	NN	I-NP	O
.	.	.	O	O

Upon	Upon	IN	B-PP	O
discharge	discharge	NN	B-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
tolerant	tolerant	JJ	B-ADJP	O
of	of	IN	B-PP	O
both	both	CC	B-NP	O
solid	solid	JJ	I-NP	O
and	and	CC	I-NP	O
liquid	liquid	JJ	I-NP	O
p.o.	p.o.	NN	I-NP	O
intake	intake	NN	I-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
independently	independently	RB	B-ADJP	O
productive	productive	JJ	I-ADJP	O
of	of	IN	B-PP	O
adequate	adequate	JJ	B-NP	O
amounts	amount	NNS	I-NP	O
of	of	IN	B-PP	O
stool	stool	NN	B-NP	O
and	and	CC	I-NP	O
flatus	flatus	NN	I-NP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

GU	GU	NN	B-NP	O
:	:	:	O	O
As	As	IN	B-SBAR	O
described	describe	VBN	B-VP	O
previously	previously	RB	B-ADVP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
known	known	JJ	I-NP	O
diagnosis	diagnosis	NN	I-NP	O
of	of	IN	B-PP	O
a	a	DT	B-NP	O
urinary	urinary	JJ	I-NP	O
tract	tract	NN	I-NP	O
infection	infection	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
Macrobid	Macrobid	NNP	B-NP	O
therapy	therapy	NN	I-NP	O
through	through	IN	B-PP	O
9/8/2004	9/8/2004	CD	B-NP	O
,	,	,	O	O
at	at	IN	B-PP	O
which	which	WDT	B-NP	O
point	point	NN	I-NP	O
this	this	DT	B-NP	O
therapy	therapy	NN	I-NP	O
was	be	VBD	B-VP	O
discontinued	discontinue	VBN	I-VP	O
.	.	.	O	O

Subsequent	Subsequent	JJ	B-NP	O
follow-up	follow-up	NN	I-NP	O
urinalyses	uranalysis	NNS	I-NP	O
demonstrated	demonstrate	VBD	B-VP	O
no	no	DT	B-NP	O
further	further	JJ	I-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
urinary	urinary	JJ	B-NP	O
tract	tract	NN	I-NP	O
infection	infection	NN	I-NP	O
.	.	.	O	O

Upon	Upon	IN	B-PP	O
completion	completion	NN	B-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
Macrobid	Macrobid	JJ	I-NP	O
antibiotic	antibiotic	JJ	I-NP	O
course	course	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
Foley	Foley	NNP	I-NP	O
catheter	catheter	NN	I-NP	O
was	be	VBD	B-VP	O
removed	remove	VBN	I-VP	O
and	and	CC	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
independently	independently	RB	B-ADJP	O
productive	productive	JJ	I-ADJP	O
of	of	IN	B-PP	O
adequate	adequate	JJ	B-NP	O
amounts	amount	NNS	I-NP	O
of	of	IN	B-PP	O
urine	urine	NN	B-NP	O
for	for	IN	B-PP	O
the	the	DT	B-NP	O
duration	duration	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
stay	stay	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
at	at	IN	B-PP	O
no	no	DT	B-NP	O
point	point	NN	I-NP	O
demonstrated	demonstrate	VBD	B-VP	O
any	any	DT	B-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
acute	acute	JJ	B-NP	O
renal	renal	JJ	I-NP	O
compromise	compromise	NN	I-NP	O
or	or	CC	I-NP	O
electrolyte	electrolyte	NN	I-NP	O
imbalance	imbalance	NN	I-NP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

Heme	Heme	NN	B-NP	B-protein
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
remained	remain	VBD	B-VP	O
stable	stable	JJ	B-ADJP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
stable	stable	JJ	I-NP	O
hematocrit	hematocrit	NN	I-NP	O
for	for	IN	B-PP	O
the	the	DT	B-NP	O
duration	duration	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
stay	stay	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
Plavix	Plavix	NN	B-NP	O
therapy	therapy	NN	I-NP	O
following	follow	VBG	B-PP	O
her	her	PRP$	B-NP	O
angiogram	angiogram	NN	I-NP	O
,	,	,	O	O
on	on	IN	B-PP	O
which	which	WDT	B-NP	O
she	she	PRP	B-NP	O
remains	remain	VBZ	B-VP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
time	time	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
discharge	discharge	NN	I-NP	O
.	.	.	O	O

DVT	DVT	NN	B-NP	O
prophylaxis	prophylaxis	NN	I-NP	O
was	be	VBD	B-VP	O
provided	provide	VBN	I-VP	O
via	via	IN	B-PP	O
subcutaneous	subcutaneous	JJ	B-NP	O
heparin	heparin	NN	I-NP	O
for	for	IN	B-PP	O
the	the	DT	B-NP	O
duration	duration	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
stay	stay	NN	I-NP	O
.	.	.	O	O

7	7	CD	B-NP	O
.	.	.	O	O

ID	ID	NN	B-NP	O
:	:	:	O	O
As	As	IN	B-SBAR	O
stated	state	VBN	B-VP	O
above	above	RB	B-ADVP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
operative	operative	JJ	I-NP	B-cell_line
cultures	culture	NNS	I-NP	I-cell_line
were	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	B-VP	O
grow	grow	VB	I-VP	O
coag.-negative	coag.-negative	JJ	B-NP	O
staph	staph	NN	I-NP	O
,	,	,	O	O
sensitive	sensitive	JJ	B-ADJP	O
to	to	TO	B-PP	O
both	both	CC	O	O
vancomycin	vancomycin	NN	B-NP	O
and	and	CC	I-NP	O
Keflex	Keflex	NN	I-NP	O
.	.	.	O	O

For	For	IN	B-PP	O
the	the	DT	B-NP	O
majority	majority	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
stay	stay	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
remained	remain	VBD	B-VP	O
on	on	IN	B-PP	O
vancomycin	vancomycin	NN	B-NP	O
therapy	therapy	NN	I-NP	O
but	but	CC	O	O
was	be	VBD	B-VP	O
transitioned	transitione	VBN	I-VP	O
to	to	TO	B-PP	O
Keflex	Keflex	NNP	B-NP	O
on	on	IN	B-PP	O
1/11/2004	1/11/2004	CD	B-NP	O
,	,	,	O	O
on	on	IN	B-PP	O
which	which	WDT	B-NP	O
she	she	PRP	B-NP	O
remained	remain	VBD	B-VP	O
for	for	IN	B-PP	O
the	the	DT	B-NP	O
duration	duration	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
stay	stay	NN	I-NP	O
.	.	.	O	O

At	At	IN	B-PP	O
the	the	DT	B-NP	O
time	time	NN	I-NP	O
of	of	IN	B-PP	O
discharge	discharge	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
been	be	VBN	I-VP	O
instructed	instruct	VBN	I-VP	O
to	to	TO	I-VP	O
complete	complete	VB	I-VP	O
an	an	DT	B-NP	O
additional	additional	JJ	I-NP	O
10-day	10-day	JJ	I-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
Keflex	Keflex	NNP	B-NP	O
therapy	therapy	NN	I-NP	O
.	.	.	O	O

Of	Of	IN	B-PP	O
note	note	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
remained	remain	VBD	B-VP	O
afebrile	afebrile	JJ	B-ADJP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
stable	stable	JJ	I-NP	O
white	white	JJ	I-NP	O
count	count	NN	I-NP	O
for	for	IN	B-PP	O
the	the	DT	B-NP	O
duration	duration	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
stay	stay	NN	I-NP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
wound	wound	NN	I-NP	O
exam	exam	NN	I-NP	O
demonstrated	demonstrate	VBD	B-VP	O
no	no	DT	B-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
further	further	JJ	B-NP	O
infection	infection	NN	I-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
ulcer	ulcer	NN	I-NP	B-DNA
site	site	NN	I-NP	I-DNA
.	.	.	O	O

8	8	CD	B-NP	O
.	.	.	O	O

Endocrine	Endocrine	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
maintained	maintain	VBD	B-VP	O
adequately	adequately	RB	B-NP	O
well-controlled	well-controlled	JJ	I-NP	O
blood	blood	NN	I-NP	O
sugars	sugar	NNS	I-NP	O
for	for	IN	B-PP	O
the	the	DT	B-NP	O
duration	duration	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
stay	stay	NN	I-NP	O
with	with	IN	B-PP	O
no	no	DT	B-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
acute	acute	JJ	B-NP	O
endocrinological	endocrinological	JJ	I-NP	O
compromise	compromise	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
subsequently	subsequently	RB	I-VP	O
cleared	clear	VBN	I-VP	O
for	for	IN	B-PP	O
discharge	discharge	NN	B-NP	O
to	to	TO	B-PP	O
a	a	DT	B-NP	O
rehabilitation	rehabilitation	NN	I-NP	O
facility	facility	NN	I-NP	O
on	on	IN	B-PP	O
postoperative	postoperative	JJ	B-NP	O
days	day	NNS	I-NP	O
10	10	CD	I-NP	O
and	and	CC	I-NP	O
3	3	CD	I-NP	O
,	,	,	I-NP	O
7/11/2004	7/11/2004	CD	I-NP	O
,	,	,	O	O
with	with	IN	B-PP	O
instructions	instruction	NNS	B-NP	O
for	for	IN	B-PP	O
follow	follow	VBP	B-VP	O
up	up	RP	B-PRT	O
.	.	.	O	O

CONDITION	CONDITION	NN	B-NP	O
ON	ON	NN	I-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
:	:	:	O	O
Patient	Patient	NN	B-NP	O
is	be	VBZ	B-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
discharged	discharge	VBN	I-VP	O
to	to	TO	B-PP	O
a	a	DT	B-NP	O
rehabilitation	rehabilitation	NN	I-NP	O
facility	facility	NN	I-NP	O
with	with	IN	B-PP	O
instructions	instruction	NNS	B-NP	O
for	for	IN	B-PP	O
follow	follow	VBP	B-VP	O
up	up	RP	B-PRT	O
.	.	.	O	O

STATUS	STATUS	NN	B-NP	O
AT	AT	NN	I-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
:	:	:	O	O
Stable	Stable	JJ	B-ADJP	O
.	.	.	O	O

DISCHARGE	DISCHARGE	NN	B-NP	O
DIAGNOSIS	DIAGNOSIS	NN	I-NP	O
:	:	:	O	O
Nonhealing	Nonheale	VBG	B-VP	O
right	right	JJ	B-NP	O
foot	foot	NN	I-NP	O
ulcer	ulcer	NN	I-NP	O
status	status	NN	I-NP	O
post	post	NN	I-NP	O
debridement	debridement	NN	I-NP	O
and	and	CC	O	O
closure	closure	NN	B-NP	O
with	with	IN	B-PP	O
an	an	DT	B-NP	O
angiogram	angiogram	NN	I-NP	O
and	and	CC	I-NP	O
angioplasty	angioplasty	NN	I-NP	O
.	.	.	O	O

CVA	CVA	NN	B-NP	B-protein
,	,	,	O	O
seizure	seizure	NN	B-NP	O
disorder	disorder	NN	I-NP	O
,	,	,	O	O
depression	depression	NN	B-NP	O
,	,	,	O	O
hypothyroidism	hypothyroidism	NN	B-NP	O
,	,	,	O	O
anemia	anemia	NN	B-NP	O
of	of	IN	B-PP	O
chronic	chronic	JJ	B-NP	O
disease	disease	NN	I-NP	O
,	,	,	O	O
SLE	SLE	NN	B-NP	O
,	,	,	O	O
interstitial	interstitial	JJ	B-NP	O
lung	lung	NN	I-NP	O
disease	disease	NN	I-NP	O
,	,	,	O	O
hypertension	hypertension	NN	B-NP	O
,	,	,	O	O
migraines	migraine	NNS	B-NP	O
,	,	,	O	O
subdural	subdural	JJ	B-NP	O
hematoma	hematoma	NN	I-NP	O
status	status	NN	I-NP	O
post	post	NN	I-NP	O
fall	fall	NN	I-NP	O
,	,	,	O	O
hypercholesterolemia	hypercholesterolemia	NN	B-NP	O
,	,	,	O	O
status	status	NN	B-NP	O
post	post	NN	I-NP	O
right	right	JJ	I-NP	O
CEA	CEA	NN	I-NP	O
,	,	,	O	O
craniotomy	craniotomy	NN	B-NP	O
and	and	CC	O	O
coronary	coronary	JJ	B-NP	O
stenting	stenting	NN	I-NP	O
.	.	.	O	O

DISCHARGE	DISCHARGE	NN	B-NP	O
MEDICATIONS	MEDICATIONS	NNS	I-NP	O
:	:	:	O	O
Tylenol	Tylenol	NN	B-NP	O
650	650	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.	q.	NN	I-NP	O
4h	4h	NN	I-NP	O
.	.	.	O	O

p.r.n.	p.r.n.	LS	B-LST	O
,	,	,	O	O
aspirin	aspirin	NN	B-NP	O
325	325	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.day	q.day	NN	I-NP	O
,	,	,	O	O
Dulcolax	Dulcolax	NN	B-NP	O
10	10	CD	I-NP	O
mg	mg	NN	I-NP	O
PR	PR	NN	I-NP	O
q.day	q.day	NN	I-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
,	,	,	O	O
Colace	Colace	NNP	B-NP	O
100	100	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
b.i.d.	b.i.d.	FW	I-ADVP	O
,	,	,	O	O
Epogen	Epogen	NN	B-NP	B-protein
40	40	CD	I-NP	I-protein
,	,	,	I-NP	O
000	000	CD	I-NP	O
units	unit	NNS	I-NP	O
SC	SC	NN	I-NP	O
q.week	q.week	NN	I-NP	O
,	,	,	O	O
iron	iron	NN	B-NP	O
325	325	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
b.i.d.	b.i.d.	FW	I-ADVP	O
,	,	,	O	O
folate	folate	VB	B-VP	O
1	1	CD	B-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.day	q.day	NN	I-NP	O
,	,	,	O	O
heparin	heparin	NN	B-NP	O
5000	5000	CD	B-NP	O
units	unit	NNS	I-NP	O
SC	SC	NNP	B-NP	O
b.i.d.	b.i.d.	NNP	I-NP	O
,	,	,	O	O
Dilaudid	Dilaudid	VBD	B-VP	O
0.5-1	0.5-1	CD	B-NP	O
mg	mg	NN	I-NP	O
IV	IV	CD	B-NP	O
q.	q.	NN	I-NP	O
4h	4h	NN	I-NP	O
.	.	.	O	O

p.r.n.	p.r.n.	NN	B-NP	O
for	for	IN	B-PP	O
pain	pain	NN	B-NP	O
,	,	,	O	O
Dilaudid	Dilaudid	VBD	B-VP	O
4-8	4-8	CD	B-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.	q.	NN	I-NP	O
3h	3h	NN	I-NP	O
.	.	.	O	O

p.r.n.	p.r.n.	NN	B-NP	O
for	for	IN	B-PP	O
pain	pain	NN	B-NP	O
,	,	,	O	O
Plaquenil	Plaquenil	NN	B-NP	O
200	200	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.day	q.day	NN	I-NP	O
,	,	,	O	O
Levoxyl	Levoxyl	NN	B-NP	O
200	200	CD	I-NP	O
mcg	mcg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.day	q.day	NN	I-NP	O
,	,	,	O	O
lisinopril	lisinopril	NN	B-NP	O
10	10	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.day	q.day	NN	I-NP	O
,	,	,	O	O
Ativan	Ativan	NNP	B-NP	O
1	1	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.h.s.	q.h.s.	NN	I-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
,	,	,	O	O
milk	milk	NN	B-NP	O
of	of	IN	B-PP	O
magnesia	magnesia	NN	B-NP	O
30	30	CD	I-NP	O
ml	ml	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.day	q.day	NN	I-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
,	,	,	O	O
Reglan	Reglan	NN	B-NP	O
10	10	CD	I-NP	O
mg	mg	NN	I-NP	O
IV	IV	CD	B-NP	O
q.	q.	NN	I-NP	O
6h	6h	NN	I-NP	O
.	.	.	O	O

p.r.n.	p.r.n.	LS	B-LST	O
,	,	,	O	O
nicotine	nicotine	NN	B-NP	O
10	10	CD	I-NP	O
mg	mg	NN	I-NP	O
per	per	IN	B-PP	O
day	day	NN	B-NP	O
topical	topical	JJ	B-NP	O
patch	patch	NN	I-NP	O
q.	q.	NN	I-NP	O
24h	24h	NN	I-NP	O
.	.	.	O	O

,	,	,	O	O
Dilantin	Dilantin	NN	B-NP	O
200	200	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
,	,	,	O	O
senna	senna	NN	B-NP	O
tablets	tablet	NNS	I-NP	O
1-2	1-2	CD	B-NP	O
tablets	tablet	NNS	I-NP	O
p.o.	p.o.	FW	I-NP	O
b.i.d.	b.i.d.	FW	I-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
,	,	,	O	O
multivitamin	multivitamin	NN	B-NP	O
1	1	CD	I-NP	O
tab	tab	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.day	q.day	NN	I-NP	O
,	,	,	O	O
Keflex	Keflex	NNP	B-NP	O
500	500	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.i.d.	q.i.d.	FW	I-NP	O
x	x	SYM	I-NP	O
40	40	CD	I-NP	O
doses	dose	NNS	I-NP	O
,	,	,	O	O
Toprol-XL	Toprol-XL	NN	B-NP	O
50	50	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.day	q.day	NN	I-NP	O
,	,	,	O	O
Neurontin	Neurontin	NN	B-NP	B-protein
300	300	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
p.o.	p.o.	FW	I-NP	I-protein
q.h.s.	q.h.s.	NN	I-NP	I-protein
,	,	,	O	O
Ultram	Ultram	NNP	B-NP	O
25	25	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.	q.	NN	I-NP	O
8h	8h	NN	I-NP	O
.	.	.	O	O

p.r.n.	p.r.n.	LS	B-LST	O
,	,	,	O	O
OxyContin	OxyContin	NNP	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.	q.	NN	I-NP	O
12h	12h	NN	I-NP	O
.	.	.	O	O

,	,	,	O	O
Zyprexa	Zyprexa	NNP	B-NP	O
5	5	CD	I-NP	O
mg	mg	NN	I-NP	O
SL	SL	NN	I-NP	O
q.h.s.	q.h.s.	NN	I-NP	O
,	,	,	O	O
Plavix	Plavix	NNP	B-NP	O
75	75	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.day	q.day	NN	I-NP	O
,	,	,	O	O
Celexa	Celexa	NNP	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.day	q.day	NN	I-NP	O
,	,	,	O	O
Zanflex	Zanflex	NN	B-NP	B-protein
4	4	CD	I-NP	I-protein
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
t.i.d.	t.i.d.	FW	I-ADVP	O
,	,	,	O	O
Advair	Advair	NNP	B-NP	O
Diskus	Diskus	NNP	I-NP	O
500/50	500/50	CD	I-NP	O
1	1	CD	I-NP	O
puff	puff	NN	I-NP	O
inhaled	inhale	VBD	B-VP	O
b.i.d.	b.i.d.	RB	B-ADVP	O
,	,	,	O	O
DuoNeb	DuoNeb	NNP	B-NP	O
3/0	3/0	CD	I-NP	O
.5	.5	CD	I-NP	O
mg	mg	NN	I-NP	O
inhaled	inhale	VBD	B-VP	O
q.	q.	NN	B-NP	O
6h	6h	NN	I-NP	O
.	.	.	O	O

p.r.n.	p.r.n.	LS	B-LST	O
,	,	,	O	O
Maalox	Maalox	NNP	B-NP	O
1-2	1-2	CD	I-NP	O
tablets	tablet	NNS	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.	q.	FW	I-NP	O
6h	6h	NN	I-NP	O
.	.	.	O	O

p.r.n.	p.r.n.	LS	B-LST	O
for	for	IN	B-PP	O
upset	upset	JJ	B-NP	O
stomach	stomach	NN	I-NP	O
.	.	.	O	O

DISCHARGE	DISCHARGE	NN	B-NP	O
INSTRUCTIONS	INSTRUCTIONS	NNS	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Patient	Patient	NN	B-NP	O
is	be	VBZ	B-VP	O
to	to	TO	B-VP	O
maintain	maintain	VB	I-VP	O
her	her	PRP$	B-NP	O
incision	incision	NN	I-NP	O
sites	site	NNS	I-NP	O
clean	clean	JJ	B-ADJP	O
and	and	CC	O	O
dry	dry	JJ	B-ADJP	O
at	at	IN	B-PP	O
all	all	DT	B-NP	O
times	time	NNS	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
may	may	MD	B-VP	O
shower	shower	VB	I-VP	O
but	but	CC	O	O
should	should	MD	B-VP	O
pat	pat	VB	I-VP	O
dry	dry	JJ	B-ADJP	O
her	her	PRP$	B-NP	O
incisions	incision	NNS	I-NP	O
afterwards	afterwards	RB	B-ADVP	O
;	;	:	O	O
no	no	DT	B-NP	O
bathing	bathing	NN	I-NP	O
or	or	CC	I-NP	O
swimming	swimming	NN	I-NP	O
until	until	IN	B-SBAR	O
further	further	JJ	B-NP	O
notice	notice	NN	I-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

No	No	DT	B-NP	O
driving	driving	NN	I-NP	O
while	while	IN	B-SBAR	O
taking	take	VBG	B-VP	O
prescription	prescription	NN	B-NP	O
narcotic	narcotic	JJ	I-NP	O
medications	medication	NNS	I-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Patient	Patient	NN	B-NP	O
may	may	MD	B-VP	O
resume	resume	VB	I-VP	O
a	a	DT	B-NP	O
regular	regular	JJ	I-NP	O
diet	diet	NN	I-NP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Patient	Patient	NN	B-NP	O
is	be	VBZ	B-VP	O
to	to	TO	B-VP	O
limit	limit	VB	I-VP	O
physical	physical	JJ	B-NP	O
exercise	exercise	NN	I-NP	O
;	;	:	O	O
no	no	DT	B-NP	O
heavy	heavy	JJ	I-NP	O
exertion	exertion	NN	I-NP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

Patient	Patient	NN	B-NP	O
is	be	VBZ	B-VP	O
to	to	TO	B-VP	O
follow	follow	VB	I-VP	O
up	up	RP	B-PRT	O
with	with	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Jewel	Jewel	NNP	I-NP	O
Craffey	Craffey	NNP	I-NP	O
within	within	IN	B-PP	O
7-10	7-10	CD	B-NP	O
days	day	NNS	I-NP	O
;	;	:	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
to	to	TO	B-VP	O
call	call	VB	I-VP	O
to	to	TO	B-VP	O
schedule	schedule	VB	I-VP	O
an	an	DT	B-NP	O
appointment	appointment	NN	I-NP	O
.	.	.	O	O

eScription	eScription	NN	B-NP	O
document	document	NN	I-NP	O
:	:	:	O	O
5-7381260	5-7381260	CD	B-NP	O
LMSSten	LMSSten	NNP	I-NP	O
Tel	Tel	NNP	I-NP	O
Dictated	Dictated	NNP	I-NP	O
By	By	NNP	I-NP	O
:	:	:	O	O
SPAID	SPAID	NNP	B-NP	O
,	,	,	O	O
WINFORD	WINFORD	NNP	B-NP	O
Attending	Attending	NNP	I-NP	O
:	:	:	O	O
DEGOLLADO	DEGOLLADO	NN	B-NP	O
,	,	,	O	O
TRACY	TRACY	NNP	B-NP	O
LESLEY	LESLEY	NNP	I-NP	O
Dictation	Dictation	NNP	I-NP	O
ID	ID	NNP	I-NP	O
8010716	8010716	CD	I-NP	O
D	D	NNP	I-NP	O
:	:	:	O	O
11/11/04	11/11/04	CD	B-NP	O
T	T	NN	I-NP	O
:	:	:	O	O
11/11/04	11/11/04	CD	B-NP	O
ATTENDING	ATTENDING	NN	I-NP	O
:	:	:	O	O
PASQUALE	PASQUALE	NN	B-NP	O
ALLEN	ALLEN	NN	I-NP	O
GAYO	GAYO	NN	I-NP	O
MD	MD	NN	I-NP	O
SERVICE	SERVICE	NN	I-NP	O
:	:	:	O	O
Vascular	Vascular	NNP	B-NP	O
Surgery	Surgery	NNP	I-NP	O
Service	Service	NNP	I-NP	O
.	.	.	O	O

HISTORY	HISTORY	NN	B-NP	O
OF	OF	IN	B-PP	O
PRESENT	PRESENT	JJ	B-NP	O
ILLNESS	ILLNESS	NN	I-NP	O
:	:	:	O	O
This	This	DT	B-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
61-year-old	61-year-old	JJ	I-NP	O
female	female	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
complicated	complicated	JJ	I-NP	O
past	past	JJ	I-NP	O
medical	medical	JJ	I-NP	O
history	history	NN	I-NP	O
notable	notable	JJ	B-ADJP	O
for	for	IN	B-PP	O
CVA	CVA	NN	B-NP	B-protein
and	and	CC	I-NP	O
peripheral	peripheral	JJ	I-NP	O
vascular	vascular	JJ	I-NP	O
disease	disease	NN	I-NP	O
with	with	IN	B-PP	O
chronic	chronic	JJ	B-NP	O
nonhealing	nonhealing	JJ	I-NP	O
foot	foot	NN	I-NP	O
ulcers	ulcer	NNS	I-NP	O
.	.	.	O	O

Patient	Patient	NN	B-NP	O
was	be	VBD	B-VP	O
seen	see	VBN	I-VP	O
a	a	DT	B-NP	O
week	week	NN	I-NP	O
prior	prior	JJ	B-ADJP	O
to	to	TO	B-PP	O
her	her	PRP$	B-NP	O
current	current	JJ	I-NP	O
admission	admission	NN	I-NP	O
in	in	IN	B-PP	O
Vascular	Vascular	NNP	B-NP	O
Clinic	Clinic	NNP	I-NP	O
for	for	IN	B-PP	O
evaluation	evaluation	NN	B-NP	O
of	of	IN	B-PP	O
nonhealing	nonhealing	JJ	B-NP	O
ulcers	ulcer	NNS	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
right	right	JJ	I-NP	O
foot	foot	NN	I-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
subsequently	subsequently	RB	I-VP	O
scheduled	schedule	VBN	I-VP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
right	right	JJ	I-NP	O
lower	low	JJR	I-NP	O
extremity	extremity	NN	I-NP	O
angiogram	angiogram	NN	I-NP	O
with	with	IN	B-PP	O
subsequent	subsequent	JJ	B-NP	O
debridement	debridement	NN	I-NP	O
planned	plan	VBN	B-VP	O
shortly	shortly	RB	B-ADVP	O
thereafter	thereafter	RB	I-ADVP	O
.	.	.	O	O

Two	Two	CD	B-NP	O
days	day	NNS	I-NP	O
prior	prior	RB	B-ADVP	O
to	to	TO	B-PP	O
admission	admission	NN	B-NP	O
,	,	,	O	O
however	however	RB	B-ADVP	O
,	,	,	O	O
the	the	DT	B-NP	O
staff	staff	NN	I-NP	O
at	at	IN	B-PP	O
her	her	PRP$	B-NP	O
rehabilitation	rehabilitation	NN	I-NP	O
facility	facility	NN	I-NP	O
noted	note	VBD	B-VP	O
increasing	increase	VBG	B-NP	O
erythema	erythema	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
area	area	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
ulcer	ulcer	NN	I-NP	O
associated	associate	VBN	B-VP	O
with	with	IN	B-PP	O
increased	increase	VBN	B-NP	O
complaints	complaint	NNS	I-NP	O
of	of	IN	B-PP	O
pain	pain	NN	B-NP	O
from	from	IN	B-PP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
.	.	.	O	O

Patient	Patient	NN	B-NP	O
was	be	VBD	B-VP	O
subsequently	subsequently	RB	I-VP	O
referred	refer	VBN	I-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
Naforest	Naforest	NNP	I-NP	O
Caview	Caview	NNP	I-NP	O
University	University	NNP	I-NP	O
Medical	Medical	NNP	I-NP	O
Center	Center	NNP	I-NP	O
Emergency	Emergency	NNP	I-NP	O
Department	Department	NNP	I-NP	O
for	for	IN	B-PP	O
further	further	JJ	B-NP	O
evaluation	evaluation	NN	I-NP	O
and	and	CC	I-NP	O
management	management	NN	I-NP	O
on	on	IN	B-PP	O
10/5/2004	10/5/2004	CD	B-NP	O
.	.	.	O	O

PAST	PAST	NNP	B-NP	O
MEDICAL	MEDICAL	NNP	I-NP	O
HISTORY	HISTORY	NNP	I-NP	O
:	:	:	O	O
Coronary	Coronary	JJ	B-NP	O
artery	artery	NN	I-NP	O
disease	disease	NN	I-NP	O
status	status	NN	I-NP	O
post	post	NN	I-NP	O
stent	stent	JJ	I-NP	O
placement	placement	NN	I-NP	O
in	in	IN	B-PP	O
1995	1995	CD	B-NP	O
,	,	,	O	O
hypertension	hypertension	NN	B-NP	O
,	,	,	O	O
hypercholesterolemia	hypercholesterolemia	NN	B-NP	O
,	,	,	O	O
peripheral	peripheral	JJ	B-NP	O
vascular	vascular	JJ	I-NP	O
disease	disease	NN	I-NP	O
,	,	,	O	O
seizure	seizure	NN	B-NP	O
disorder	disorder	NN	I-NP	O
,	,	,	O	O
hypothyroidism	hypothyroidism	NN	B-NP	O
,	,	,	O	O
systemic	systemic	JJ	B-NP	O
lupus	lupus	NN	I-NP	O
erythematous	erythematous	JJ	B-ADJP	O
,	,	,	O	O
anemia	anemia	NN	B-NP	O
of	of	IN	B-PP	O
chronic	chronic	JJ	B-NP	O
disease	disease	NN	I-NP	O
,	,	,	O	O
history	history	NN	B-NP	O
of	of	IN	B-PP	O
stroke	stroke	NN	B-NP	O
with	with	IN	B-PP	O
right-sided	right-sided	JJ	B-NP	O
hemiparesis	hemiparesis	NN	I-NP	O
since	since	IN	B-PP	O
1996	1996	CD	B-NP	O
,	,	,	O	O
and	and	CC	O	O
associated	associate	VBN	B-VP	O
high	high	JJ	B-NP	O
tone	tone	NN	I-NP	O
and	and	CC	O	O
spasticity	spasticity	NN	B-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
right	right	JJ	I-NP	O
lower	low	JJR	I-NP	O
extremity	extremity	NN	I-NP	O
,	,	,	O	O
history	history	NN	B-NP	O
of	of	IN	B-PP	O
subdural	subdural	JJ	B-NP	O
hematoma	hematoma	NN	I-NP	O
secondary	secondary	JJ	B-ADJP	O
to	to	TO	B-PP	O
a	a	DT	B-NP	O
fall	fall	NN	I-NP	O
,	,	,	O	O
migraines	migraine	NNS	B-NP	O
,	,	,	O	O
chronic	chronic	JJ	B-NP	O
pain	pain	NN	I-NP	O
syndrome	syndrome	NN	I-NP	O
,	,	,	O	O
narcotic	narcotic	JJ	B-NP	O
dependency	dependency	NN	I-NP	O
,	,	,	O	O
interstitial	interstitial	JJ	B-NP	O
lung	lung	NN	I-NP	O
disease	disease	NN	I-NP	O
secondary	secondary	JJ	B-ADJP	O
to	to	TO	B-PP	O
lupus	lupus	NN	B-NP	O
,	,	,	O	O
bipolar	bipolar	JJ	B-NP	O
disorder	disorder	NN	I-NP	O
,	,	,	O	O
chronic	chronic	JJ	B-NP	O
constipation	constipation	NN	I-NP	O
.	.	.	O	O

PAST	PAST	NN	B-NP	O
SURGICAL	SURGICAL	NN	I-NP	O
HISTORY	HISTORY	NN	I-NP	O
:	:	:	O	O
Right	Right	NN	B-NP	O
CEA	CEA	NN	I-NP	O
in	in	IN	B-PP	O
1999	1999	CD	B-NP	O
,	,	,	O	O
craniotomy	craniotomy	NN	B-NP	O
for	for	IN	B-PP	O
subdural	subdural	JJ	B-NP	O
hematoma	hematoma	NN	I-NP	O
in	in	IN	B-PP	O
1999	1999	CD	B-NP	O
.	.	.	O	O

HOME	HOME	NN	B-NP	O
MEDICATIONS	MEDICATIONS	NNS	I-NP	O
:	:	:	O	O
Premarin	Premarin	NN	B-NP	O
0.65	0.65	CD	I-NP	O
mg	mg	NN	I-NP	O
q.day	q.day	NN	I-NP	O
,	,	,	O	O
iron	iron	NN	B-NP	O
gluconate	gluconate	NN	I-NP	O
300	300	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.day	q.day	NN	I-NP	O
,	,	,	O	O
folate	folate	VB	B-VP	O
1	1	CD	B-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.day	q.day	NN	I-NP	O
,	,	,	O	O
multivitamin	multivitamin	NN	B-NP	O
p.o.	p.o.	NN	I-NP	O
q.day	q.day	NN	I-NP	O
,	,	,	O	O
Plaquenil	Plaquenil	NN	B-NP	O
200	200	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.day	q.day	NN	I-NP	O
,	,	,	O	O
Levoxyl	Levoxyl	NN	B-NP	O
200	200	CD	I-NP	O
mcg	mcg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.day	q.day	NN	I-NP	O
,	,	,	O	O
Toprol-XL	Toprol-XL	NN	B-NP	O
50	50	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.day	q.day	NN	I-NP	O
,	,	,	O	O
lisinopril	lisinopril	NN	B-NP	O
10	10	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.day	q.day	NN	I-NP	O
,	,	,	O	O
nicotine	nicotine	NN	B-NP	O
patch	patch	NN	I-NP	O
14	14	CD	I-NP	O
mcg	mcg	NN	I-NP	O
topical	topical	JJ	I-NP	O
,	,	,	I-NP	O
Celexa	Celexa	NNP	I-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.day	q.day	NN	I-NP	O
,	,	,	O	O
macrobid	macrobid	NN	B-NP	O
100	100	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
b.i.d.	b.i.d.	FW	I-ADVP	O
,	,	,	O	O
sodium	sodium	NN	B-NP	O
chloride	chloride	NN	I-NP	O
tablets	tablet	NNS	I-NP	O
,	,	,	O	O
hydralazine	hydralazine	NN	B-NP	O
10	10	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
t.i.d.	t.i.d.	FW	I-ADVP	O
,	,	,	O	O
Ultram	Ultram	NNP	B-NP	O
25	25	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.h.s.	q.h.s.	NN	I-NP	O
,	,	,	O	O
Neurontin	Neurontin	NN	B-NP	B-protein
100	100	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
p.o.	p.o.	FW	I-NP	I-protein
q.h.s.	q.h.s.	FW	I-NP	I-protein
Dilantin	Dilantin	NN	I-NP	I-protein
200	200	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
p.o.	p.o.	FW	I-NP	O
q.a.m.	q.a.m.	NN	I-NP	O
,	,	,	O	O
100	100	CD	B-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.afternoon	q.afternoon	NN	I-NP	O
,	,	,	O	O
200	200	CD	B-NP	O
p.o.	p.o.	NN	I-NP	O
q.p.m.	q.p.m.	NN	I-NP	O
Lipitor	Lipitor	NN	I-NP	O
10	10	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.day	q.day	NN	I-NP	O
,	,	,	O	O
Advair	Advair	NNP	B-NP	O
Diskus	Diskus	NNP	I-NP	O
500/50	500/50	CD	I-NP	O
1	1	CD	I-NP	O
puff	puff	NN	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
,	,	,	O	O
Colace	Colace	NNP	B-NP	O
100	100	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
b.i.d.	b.i.d.	FW	I-ADVP	O
,	,	,	O	O
Zyprexa	Zyprexa	NNP	B-NP	O
5	5	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.h.s.	q.h.s.	FW	I-NP	O
p.r.n.	p.r.n.	FW	I-NP	O
ALLERGIES	ALLERGIES	NNPS	I-NP	O
:	:	:	O	O
Sulfa	Sulfa	NNP	B-NP	O
.	.	.	O	O

Question	Question	NN	B-NP	O
of	of	IN	B-PP	O
allergy	allergy	NN	B-NP	O
to	to	TO	B-PP	O
Levaquin	Levaquin	NNP	B-NP	O
.	.	.	O	O

Questionable	Questionable	JJ	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
adverse	adverse	JJ	B-NP	O
reactions	reaction	NNS	I-NP	O
to	to	TO	B-PP	O
Prozac	Prozac	NN	B-NP	O
,	,	,	O	O
trazodone	trazodone	NN	B-NP	O
,	,	,	O	O
baclofen	baclofen	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
narcotics	narcotic	NNS	B-NP	O
.	.	.	O	O

SOCIAL	SOCIAL	JJ	B-NP	O
HISTORY	HISTORY	NN	I-NP	O
:	:	:	O	O
Patient	Patient	NN	B-NP	O
previously	previously	RB	B-VP	O
lived	live	VBN	I-VP	O
with	with	IN	B-PP	O
husband	husband	NN	B-NP	O
.	.	.	O	O

Patient	Patient	NN	B-NP	O
has	have	VBZ	B-VP	O
been	be	VBN	I-VP	O
wheelchair-dependent	wheelchair-dependent	JJ	B-ADJP	O
for	for	IN	B-PP	O
the	the	DT	B-NP	O
past	past	JJ	I-NP	O
four	four	CD	I-NP	O
weeks	week	NNS	I-NP	O
due	due	JJ	B-ADJP	O
to	to	TO	B-PP	O
her	her	PRP$	B-NP	O
chronic	chronic	JJ	I-NP	O
ulcers	ulcer	NNS	I-NP	O
.	.	.	O	O

Smokes	Smokes	NNP	B-NP	O
1-2	1-2	CD	I-NP	O
packs	pack	NNS	I-NP	O
per	per	IN	B-PP	O
day	day	NN	B-NP	O
until	until	IN	B-SBAR	O
approximately	approximately	RB	B-NP	O
four	four	CD	I-NP	O
weeks	week	NNS	I-NP	O
prior	prior	RB	B-ADVP	O
to	to	TO	B-PP	O
admission	admission	NN	B-NP	O
.	.	.	O	O

PHYSICAL	PHYSICAL	NN	B-NP	O
EXAMINATION	EXAMINATION	NN	I-NP	O
IN	IN	IN	B-PP	O
THE	THE	DT	B-NP	O
EMERGENCY	EMERGENCY	NN	I-NP	O
DEPARTMENT	DEPARTMENT	NN	I-NP	O
:	:	:	O	O
Afebrile	Afebrile	NN	B-NP	O
.	.	.	O	O

Heart	Heart	NN	B-NP	O
rate	rate	NN	I-NP	O
66	66	CD	I-NP	O
,	,	,	O	O
blood	blood	NN	B-NP	O
pressure	pressure	NN	I-NP	O
110/48	110/48	CD	I-NP	O
,	,	,	O	O
breathing	breathing	NN	B-NP	O
18	18	CD	I-NP	O
,	,	,	O	O
satting	satte	VBG	B-VP	O
98	98	CD	B-NP	O
%	%	NN	I-NP	O
on	on	IN	B-PP	O
room	room	NN	B-NP	O
air	air	NN	I-NP	O
.	.	.	O	O

Patient	Patient	NN	B-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
in	in	IN	B-PP	O
moderate	moderate	JJ	B-NP	O
distress	distress	NN	I-NP	O
secondary	secondary	JJ	B-ADJP	O
to	to	TO	B-VP	O
discomfort	discomfort	VB	I-VP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
right	right	JJ	I-NP	O
lower	low	JJR	I-NP	O
extremity	extremity	NN	I-NP	O
with	with	IN	B-PP	O
associated	associate	VBN	B-NP	O
spasm	spasm	NN	I-NP	O
and	and	CC	I-NP	O
foot	foot	NN	I-NP	O
pain	pain	NN	I-NP	O
.	.	.	O	O

Patient	Patient	NNP	B-NP	O
's	's	POS	B-NP	O
lungs	lung	NNS	I-NP	O
were	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
clear	clear	JJ	B-ADJP	O
to	to	TO	B-PP	O
auscultation	auscultation	NN	B-NP	O
bilaterally	bilaterally	RB	B-ADVP	O
.	.	.	O	O

A	A	DT	B-NP	O
well-healed	well-healed	JJ	I-NP	O
right	right	JJ	I-NP	O
CEA	CEA	NN	I-NP	O
scar	scar	NN	I-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
neck	neck	NN	I-NP	O
.	.	.	O	O

Patient	Patient	NN	B-NP	O
's	's	POS	B-NP	O
heart	heart	NN	I-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
a	a	DT	B-NP	O
regular	regular	JJ	I-NP	O
rate	rate	NN	I-NP	O
and	and	CC	O	O
rhythm	rhythm	NN	B-NP	O
with	with	IN	B-PP	O
no	no	DT	B-NP	O
murmurs	murmur	NNS	I-NP	O
,	,	,	I-NP	O
rubs	rub	NNS	I-NP	O
or	or	CC	I-NP	O
gallops	gallop	NNS	I-NP	O
.	.	.	O	O

Patient	Patient	NN	B-NP	O
's	's	POS	B-NP	O
abdomen	abdomen	NN	I-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
soft	soft	JJ	B-ADJP	O
,	,	,	I-ADJP	O
nondistended	nondistended	JJ	I-ADJP	O
and	and	CC	I-ADJP	O
nontender	nontender	JJ	I-ADJP	O
.	.	.	O	O

Extremity	Extremity	NN	B-NP	O
exam	exam	NN	I-NP	O
demonstrated	demonstrate	VBD	B-VP	O
a	a	DT	B-NP	O
right	right	JJ	I-NP	O
leg	leg	NN	I-NP	O
with	with	IN	B-PP	O
severe	severe	JJ	B-NP	O
knee	knee	NN	I-NP	O
contracture	contracture	NN	I-NP	O
and	and	CC	I-NP	O
spasm	spasm	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
left	left	JJ	I-NP	O
side	side	NN	I-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
normal	normal	JJ	B-ADJP	O
.	.	.	O	O

The	The	DT	B-NP	O
left	left	JJ	I-NP	O
foot	foot	NN	I-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
two	two	CD	B-NP	O
small	small	JJ	I-NP	O
clean	clean	JJ	I-NP	O
ulcers	ulcer	NNS	I-NP	O
,	,	,	O	O
one	one	CD	B-NP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
medial	medial	JJ	I-NP	O
bunion	bunion	NN	I-NP	O
and	and	CC	O	O
one	one	CD	B-NP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
tip	tip	NN	I-NP	B-protein
of	of	IN	B-PP	O
the	the	DT	B-NP	O
medial	medial	JJ	I-NP	O
great	great	JJ	I-NP	O
toe	toe	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
right	right	JJ	I-NP	O
foot	foot	NN	I-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
a	a	DT	B-NP	O
large	large	JJ	I-NP	O
dark	dark	JJ	I-NP	O
necrotic	necrotic	JJ	I-NP	O
pressure	pressure	NN	I-NP	O
wound	wound	NN	I-NP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
lateral	lateral	JJ	I-NP	O
aspect	aspect	NN	I-NP	O
and	and	CC	I-NP	O
plantar	plantar	NN	I-NP	O
aspect	aspect	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
mid	mid	JJ	I-NP	O
foot	foot	NN	I-NP	O
,	,	,	O	O
an	an	DT	B-NP	O
open	open	JJ	I-NP	B-DNA
infected-appearing	infected-appearing	JJ	I-NP	I-DNA
ulcer	ulcer	NN	I-NP	I-DNA
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
medial	medial	JJ	I-NP	O
forefoot	forefoot	NN	I-NP	O
with	with	IN	B-PP	O
surrounding	surround	VBG	B-VP	O
erythema	erythema	NN	B-NP	O
and	and	CC	O	O
a	a	DT	B-NP	O
greenish	greenish	JJ	I-NP	O
exudate	exudate	NN	I-NP	O
of	of	IN	B-PP	O
film	film	NN	B-NP	O
.	.	.	O	O

Pulse	Pulse	NN	B-NP	B-protein
exam	exam	NN	I-NP	I-protein
demonstrated	demonstrate	VBD	B-VP	I-protein
2	2	CD	B-NP	I-protein
+	+	SYM	I-NP	O
pulses	pulse	NNS	I-NP	O
in	in	IN	B-PP	O
bilateral	bilateral	JJ	B-NP	O
carotids	carotid	NNS	I-NP	O
,	,	,	O	O
radials	radial	NNS	B-NP	O
,	,	,	O	O
and	and	CC	O	O
femorals	femoral	NNS	B-NP	O
.	.	.	O	O

Right	Right	RB	B-NP	O
popliteal	popliteal	JJ	I-NP	O
biphasic	biphasic	JJ	I-NP	O
Doppler	Doppler	NNP	I-NP	O
pulses	pulse	NNS	I-NP	O
noted	note	VBD	B-VP	O
.	.	.	O	O

No	No	DT	B-NP	O
pulses	pulse	NNS	I-NP	O
were	be	VBD	B-VP	O
able	able	JJ	B-ADJP	O
to	to	TO	B-VP	O
be	be	VB	I-VP	O
distinguished	distinguish	VBN	I-VP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
right	right	JJ	I-NP	O
foot	foot	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
left	left	JJ	I-NP	O
foot	foot	NN	I-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
biphasic	biphasic	JJ	B-NP	O
signals	signal	NNS	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
DP	DP	NN	I-NP	O
and	and	CC	I-NP	O
PT	PT	NN	I-NP	O
by	by	IN	B-PP	O
Doppler	Doppler	NNP	B-NP	O
.	.	.	O	O

LABORATORY	LABORATORY	NN	B-NP	O
STUDIES	STUDIES	NNS	I-NP	O
UPON	UPON	NN	I-NP	O
ADMISSION	ADMISSION	NN	I-NP	O
:	:	:	O	O
Sodium	Sodium	NN	B-NP	O
136	136	CD	I-NP	O
,	,	,	O	O
potassium	potassium	NN	B-NP	O
4.8	4.8	CD	I-NP	O
,	,	,	O	O
chloride	chloride	NN	B-NP	O
101	101	CD	I-NP	O
,	,	,	O	O
bicarbonate	bicarbonate	NN	B-NP	O
23	23	CD	I-NP	O
,	,	,	O	O
BUN	BUN	NN	B-NP	B-DNA
21	21	CD	I-NP	I-DNA
,	,	,	O	O
creatinine	creatinine	NN	B-NP	O
1.1	1.1	CD	I-NP	O
,	,	,	O	O
glucose	glucose	NN	B-NP	O
74	74	CD	I-NP	O
.	.	.	O	O

ALT	ALT	NN	B-NP	O
was	be	VBD	B-VP	O
36	36	CD	B-NP	O
,	,	,	O	O
AST	AST	NN	B-NP	O
33	33	CD	I-NP	O
,	,	,	O	O
alk	alk	NN	B-NP	O
phos	pho	NNS	I-NP	O
173	173	CD	B-NP	O
,	,	,	O	O
total	total	JJ	B-NP	O
bili	bili	NNS	I-NP	O
0.3	0.3	CD	B-NP	O
,	,	,	O	O
albumin	albumin	NN	B-NP	O
4.0	4.0	CD	I-NP	O
.	.	.	O	O

White	White	JJ	B-NP	O
blood	blood	NN	I-NP	O
cell	cell	NN	I-NP	O
count	count	NN	I-NP	O
was	be	VBD	B-VP	O
9.6	9.6	CD	B-NP	O
,	,	,	O	O
hematocrit	hematocrit	NN	B-NP	B-protein
36.2	36.2	CD	I-NP	I-protein
,	,	,	O	O
and	and	CC	O	O
platelets	platelet	NNS	B-NP	B-cell_type
232	232	CD	B-NP	O
.	.	.	O	O

PT	PT	NN	B-NP	B-protein
13.4	13.4	CD	I-NP	I-protein
,	,	,	O	O
PTT	PTT	NN	B-NP	B-protein
28.1	28.1	CD	I-NP	I-protein
,	,	,	O	O
INR	INR	NN	B-NP	B-protein
1.0	1.0	CD	I-NP	I-protein
.	.	.	O	O

Chest	Ch	JJS	B-NP	O
x-ray	x-ray	NN	I-NP	B-DNA
demonstrated	demonstrate	VBD	B-VP	O
a	a	DT	B-NP	O
mild	mild	JJ	I-NP	O
interstitial	interstitial	JJ	I-NP	O
disease	disease	NN	I-NP	O
with	with	IN	B-PP	O
multiple	multiple	JJ	B-NP	O
old	old	JJ	I-NP	O
right	right	JJ	I-NP	O
rib	rib	NN	I-NP	O
fractures	fracture	NNS	I-NP	O
.	.	.	O	O

X-ray	X-ray	NN	B-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
feet	foot	NNS	I-NP	O
demonstrated	demonstrate	VBD	B-VP	O
bilateral	bilateral	JJ	B-NP	O
osteopenia	osteopenia	NN	I-NP	O
with	with	IN	B-PP	O
no	no	DT	B-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
osteomyelitis	osteomyelitis	NN	B-NP	O
in	in	IN	B-PP	O
either	either	DT	B-NP	O
foot	foot	NN	I-NP	O
.	.	.	O	O

EKG	EKG	NN	B-NP	B-protein
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
normal	normal	JJ	B-ADJP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
normal	normal	JJ	I-NP	O
sinus	sinus	NN	I-NP	O
rhythm	rhythm	NN	I-NP	O
at	at	IN	B-PP	O
63	63	CD	B-NP	O
.	.	.	O	O

HOSPITAL	HOSPITAL	JJ	B-NP	O
COURSE	COURSE	NN	I-NP	O
:	:	:	O	O
Patient	Patient	NN	B-NP	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
Vascular	Vascular	NNP	I-NP	O
Surgery	Surgery	NNP	I-NP	O
Service	Service	NNP	I-NP	O
on	on	IN	B-PP	O
10/5/2004	10/5/2004	CD	B-NP	O
for	for	IN	B-PP	O
further	further	JJ	B-NP	O
evaluation	evaluation	NN	I-NP	O
and	and	CC	I-NP	O
management	management	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
empirically	empirically	RB	I-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
vancomycin	vancomycin	NN	B-NP	O
and	and	CC	I-NP	O
ceftazidime	ceftazidime	NN	I-NP	O
with	with	IN	B-PP	O
wet-to-dry	wet-to-dry	JJ	B-NP	O
dressings	dressing	NNS	I-NP	O
applied	apply	VBN	B-VP	O
to	to	TO	B-PP	O
her	her	PRP$	B-NP	O
right	right	JJ	I-NP	O
foot	foot	NN	I-NP	O
wound	wound	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
also	also	RB	I-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
prior	prior	JJ	I-NP	O
dose	dose	NN	I-NP	O
of	of	IN	B-PP	O
Macrobid	Macrobid	NNP	B-NP	O
for	for	IN	B-PP	O
previously-diagnosed	previously-diagnosed	JJ	B-NP	O
UTI	UTI	NN	I-NP	O
with	with	IN	B-PP	O
her	her	PRP$	B-NP	O
antibiotic	antibiotic	JJ	I-NP	O
regimen	regimen	NN	I-NP	O
to	to	TO	B-VP	O
be	be	VB	I-VP	O
discontinued	discontinue	VBN	I-VP	O
for	for	IN	B-PP	O
this	this	DT	B-NP	O
purpose	purpose	NN	I-NP	O
on	on	IN	B-PP	O
9/8/2004	9/8/2004	CD	B-NP	O
.	.	.	O	O

An	An	DT	B-NP	O
angiogram	angiogram	NN	I-NP	O
performed	perform	VBN	B-VP	O
on	on	IN	B-PP	O
hospital	hospital	NN	B-NP	O
day	day	NN	I-NP	O
#	#	#	B-NP	O
2	2	CD	I-NP	O
,	,	,	O	O
revealed	reveal	VBD	B-VP	O
a	a	DT	B-NP	O
right	right	JJ	I-NP	O
external	external	JJ	I-NP	O
iliac	iliac	JJ	I-NP	O
occlusion	occlusion	NN	I-NP	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
stented	stente	VBN	I-VP	O
near	near	IN	B-PP	O
the	the	DT	B-NP	O
bifurcation	bifurcation	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
internal	internal	JJ	I-NP	O
and	and	CC	I-NP	O
external	external	JJ	I-NP	O
iliac	iliac	JJ	I-NP	O
vessels	vessel	NNS	I-NP	O
.	.	.	O	O

A	A	DT	B-NP	O
distal	distal	JJ	I-NP	O
stenosis	stenosis	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
external	external	JJ	I-NP	O
iliac	iliac	NN	I-NP	O
was	be	VBD	B-VP	O
opened	open	VBN	I-VP	O
with	with	IN	B-PP	O
balloon	balloon	NN	B-NP	O
angioplasty	angioplasty	JJ	B-ADJP	O
to	to	TO	B-PP	O
good	good	JJ	B-NP	O
effect	effect	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
sustained	sustain	VBD	B-VP	O
a	a	DT	B-NP	O
mild	mild	JJ	I-NP	O
groin	groin	NN	I-NP	O
hematoma	hematoma	NN	I-NP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
left	left	NN	I-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
access	access	NN	I-NP	O
site	site	NN	I-NP	O
but	but	CC	O	O
had	have	VBD	B-VP	O
no	no	DT	B-NP	O
change	change	NN	I-NP	O
in	in	IN	B-PP	O
her	her	PRP$	B-NP	O
pulse	pulse	NN	I-NP	O
exam	exam	NN	I-NP	O
there	there	EX	B-NP	O
afterwards	afterwards	RB	B-ADVP	O
.	.	.	O	O

Following	Follow	VBG	B-PP	O
her	her	PRP$	B-NP	O
angiogram	angiogram	NN	I-NP	O
and	and	CC	I-NP	O
percutaneous	percutaneous	JJ	I-NP	O
intervention	intervention	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
demonstrate	demonstrate	VB	I-VP	O
excellent	excellent	JJ	B-NP	O
right	right	RB	I-NP	O
lower	low	JJR	I-NP	O
extremity	extremity	NN	I-NP	O
DP	DP	NN	I-NP	O
and	and	CC	I-NP	O
PT	PT	NN	I-NP	O
pulses	pulse	NNS	I-NP	O
which	which	WDT	B-NP	O
remained	remain	VBD	B-VP	O
palpable	palpable	JJ	B-ADJP	O
through	through	IN	B-PP	O
the	the	DT	B-NP	O
duration	duration	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
hospital	hospital	NN	I-NP	O
course	course	NN	I-NP	O
.	.	.	O	O

On	On	IN	B-PP	O
hospital	hospital	NN	B-NP	O
day	day	NN	I-NP	O
#	#	#	B-NP	O
3	3	CD	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
brought	bring	VBN	I-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
operating	operating	NN	I-NP	O
room	room	NN	I-NP	O
for	for	IN	B-PP	O
debridement	debridement	NN	B-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
right	right	JJ	I-NP	O
foot	foot	NN	I-NP	O
.	.	.	O	O

For	For	IN	B-PP	O
a	a	DT	B-NP	O
detailed	detailed	JJ	I-NP	O
description	description	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
operative	operative	JJ	I-NP	O
procedure	procedure	NN	I-NP	O
,	,	,	O	O
please	please	VB	B-VP	O
the	the	DT	B-NP	O
relevant	relevant	JJ	I-NP	O
operative	operative	JJ	I-NP	O
note	note	NN	I-NP	O
.	.	.	O	O

Patient	Patient	NN	B-NP	O
tolerated	tolerate	VBD	B-VP	O
the	the	DT	B-NP	O
procedure	procedure	NN	I-NP	O
well	well	RB	B-ADVP	O
and	and	CC	O	O
during	during	IN	B-PP	O
the	the	DT	B-NP	O
procedure	procedure	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
ulcer	ulcer	NN	I-NP	O
base	base	NN	I-NP	O
was	be	VBD	B-VP	O
found	find	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
contiguous	contiguous	JJ	B-ADJP	O
with	with	IN	B-PP	O
the	the	DT	B-NP	O
first	first	JJ	I-NP	O
metatarsal	metatarsal	JJ	I-NP	O
head	head	NN	I-NP	O
periosteum	periosteum	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
therefore	therefore	RB	B-ADVP	O
,	,	,	O	O
a	a	DT	B-NP	O
metatarsal	metatarsal	JJ	I-NP	O
head	head	NN	I-NP	O
excision	excision	NN	I-NP	O
was	be	VBD	B-VP	O
performed	perform	VBN	I-VP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
great	great	JJ	I-NP	O
toe	toe	NN	I-NP	O
was	be	VBD	B-VP	O
left	leave	VBN	I-VP	O
in	in	IN	B-PP	O
place	place	NN	B-NP	O
with	with	IN	B-PP	O
moderate	moderate	JJ	B-NP	O
debridement	debridement	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
deep	deep	JJ	I-NP	O
tissues	tissue	NNS	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
ulcers	ulcer	NNS	I-NP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
lateral	lateral	JJ	I-NP	O
right	right	JJ	I-NP	O
foot	foot	NN	I-NP	O
were	be	VBD	B-VP	O
not	not	RB	I-VP	O
debrided	debride	VBN	I-VP	O
at	at	IN	B-PP	O
this	this	DT	B-NP	O
time	time	NN	I-NP	O
.	.	.	O	O

Following	Follow	VBG	B-PP	O
her	her	PRP$	B-NP	O
procedure	procedure	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
empirically	empirically	RB	I-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
vancomycin	vancomycin	NN	B-NP	O
and	and	CC	I-NP	O
ceftazidime	ceftazidime	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	B-cell_line
operative	operative	JJ	I-NP	I-cell_line
cultures	culture	NNS	I-NP	I-cell_line
subsequently	subsequently	RB	B-ADVP	O
grew	grow	VBD	B-VP	O
out	out	RP	B-PRT	O
coagulase-negative	coagulase-negative	JJ	B-NP	O
staph	staph	NN	I-NP	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
sensitive	sensitive	JJ	B-ADJP	O
to	to	TO	B-PP	O
both	both	CC	O	O
Keflex	Keflex	NNP	B-NP	O
and	and	CC	O	O
vancomycin	vancomycin	NN	B-NP	O
.	.	.	O	O

At	At	IN	B-PP	O
this	this	DT	B-NP	O
point	point	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
switched	switch	VBN	I-VP	O
to	to	TO	B-PP	O
vancomycin	vancomycin	NN	B-NP	O
therapy	therapy	NN	I-NP	O
only	only	RB	B-ADVP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
VAC	VAC	NN	B-NP	O
therapy	therapy	NN	I-NP	O
through	through	IN	B-PP	O
postoperative	postoperative	JJ	B-NP	B-protein
day	day	NN	I-NP	I-protein
#	#	#	B-NP	I-protein
3	3	CD	I-NP	I-protein
.	.	.	O	O

At	At	IN	B-PP	O
this	this	DT	B-NP	O
point	point	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
VAC	VAC	NN	I-NP	O
dressing	dressing	NN	I-NP	O
was	be	VBD	B-VP	O
changed	change	VBN	I-VP	O
to	to	TO	B-VP	O
demonstrate	demonstrate	VB	I-VP	O
a	a	DT	B-NP	O
well-vascularized	well-vascularized	JJ	I-NP	O
actively	actively	RB	I-NP	O
bleeding	bleed	VBG	I-NP	O
wound	wound	NN	B-NP	O
with	with	IN	B-PP	O
granulation	granulation	NN	B-NP	O
tissue	tissue	NN	I-NP	O
and	and	CC	O	O
no	no	DT	B-NP	O
signs	sign	NNS	I-NP	O
of	of	IN	B-PP	O
wound	wound	NN	B-NP	O
necrosis	necrosis	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
remained	remain	VBD	B-VP	O
in	in	IN	B-PP	O
stable	stable	JJ	B-NP	O
condition	condition	NN	I-NP	O
through	through	IN	B-PP	O
postoperative	postoperative	JJ	B-NP	O
day	day	NN	I-NP	O
#	#	#	B-NP	O
7	7	CD	I-NP	O
at	at	IN	B-PP	O
which	which	WDT	B-NP	O
point	point	NN	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
returned	return	VBN	I-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
operating	operating	NN	I-NP	O
room	room	NN	I-NP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
great	great	JJ	I-NP	O
toe	toe	NN	I-NP	O
amputation	amputation	NN	I-NP	O
and	and	CC	O	O
definitive	definitive	JJ	B-NP	O
closure	closure	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
right	right	JJ	I-NP	O
foot	foot	NN	I-NP	O
wound	wound	NN	I-NP	O
.	.	.	O	O

For	For	IN	B-PP	O
a	a	DT	B-NP	O
detailed	detailed	JJ	I-NP	O
description	description	NN	I-NP	O
of	of	IN	B-PP	O
this	this	DT	B-NP	O
operative	operative	JJ	I-NP	O
procedure	procedure	NN	I-NP	O
,	,	,	O	O
please	please	NN	B-NP	O
see	see	VBP	B-VP	O
the	the	DT	B-NP	O
relevant	relevant	JJ	I-NP	O
operative	operative	JJ	I-NP	O
note	note	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
tolerated	tolerate	VBD	B-VP	O
the	the	DT	B-NP	O
procedure	procedure	NN	I-NP	O
well	well	RB	B-ADVP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
subsequently	subsequently	RB	I-VP	O
returned	return	VBN	I-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
Regular	Regular	JJ	I-NP	O
Outpatient	Outpatient	NN	I-NP	O
Floor	Floor	NN	I-NP	O
where	where	WRB	B-ADVP	O
she	she	PRP	B-NP	O
remained	remain	VBD	B-VP	O
for	for	IN	B-PP	O
the	the	DT	B-NP	O
duration	duration	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
stay	stay	NN	I-NP	O
.	.	.	O	O

A	A	DT	B-NP	O
general	general	JJ	I-NP	O
overview	overview	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
hospital	hospital	NN	I-NP	O
course	course	NN	I-NP	O
by	by	IN	B-PP	O
system	system	NN	B-NP	O
is	be	VBZ	B-VP	O
as	as	IN	B-SBAR	O
follows	follow	VBZ	B-VP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Neurological	Neurological	JJ	B-ADJP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
demonstrated	demonstrate	VBD	B-VP	O
significant	significant	JJ	B-NP	O
issues	issue	NNS	I-NP	O
with	with	IN	B-PP	O
pain	pain	NN	B-NP	O
control	control	NN	I-NP	O
for	for	IN	B-PP	O
the	the	DT	B-NP	O
duration	duration	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
stay	stay	NN	I-NP	O
.	.	.	O	O

A	A	DT	B-NP	O
fair	fair	JJ	I-NP	O
amount	amount	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
pain	pain	NN	I-NP	O
was	be	VBD	B-VP	O
determined	determine	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
secondary	secondary	JJ	B-ADJP	O
to	to	TO	B-PP	O
her	her	PRP$	B-NP	O
right	right	JJ	I-NP	O
foot	foot	NN	I-NP	O
ulcer	ulcer	NN	I-NP	O
;	;	:	O	O
however	however	RB	B-ADVP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
also	also	RB	I-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
significant	significant	JJ	B-NP	O
pain	pain	NN	I-NP	O
associated	associate	VBN	B-VP	O
with	with	IN	B-PP	O
her	her	PRP$	B-NP	O
contracted	contract	VBD	B-VP	O
right	right	RB	B-NP	O
lower	low	JJR	I-NP	O
extremity	extremity	NN	I-NP	O
.	.	.	O	O

For	For	IN	B-PP	O
a	a	DT	B-NP	O
time	time	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
placed	place	VBN	I-VP	O
in	in	IN	B-PP	O
a	a	DT	B-NP	O
right	right	JJ	I-NP	O
lower	low	JJR	I-NP	O
extremity	extremity	NN	I-NP	O
extension	extension	NN	I-NP	O
brace	brace	NN	I-NP	O
which	which	WDT	B-NP	O
provided	provide	VBD	B-VP	O
some	some	DT	B-NP	O
measure	measure	NN	I-NP	O
of	of	IN	B-PP	O
relief	relief	NN	B-NP	O
;	;	:	O	O
however	however	RB	B-ADVP	O
,	,	,	O	O
upon	upon	IN	B-PP	O
regular	regular	JJ	B-NP	O
examination	examination	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
right	right	JJ	I-NP	O
lower	low	JJR	I-NP	O
extremity	extremity	NN	I-NP	O
,	,	,	O	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
that	that	IN	B-SBAR	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
gradually	gradually	RB	I-VP	O
developing	develop	VBG	I-VP	O
pressure	pressure	NN	B-NP	O
ulcers	ulcer	NNS	I-NP	O
secondary	secondary	JJ	B-ADJP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
extension	extension	NN	I-NP	O
brace	brace	NN	I-NP	O
.	.	.	O	O

A	A	DT	B-NP	O
Neurology	Neurology	NNP	I-NP	O
and	and	CC	I-NP	O
Pain	Pain	NNP	I-NP	O
Service	Service	NNP	I-NP	O
consultation	consultation	NN	I-NP	O
was	be	VBD	B-VP	O
obtained	obtain	VBN	I-VP	O
and	and	CC	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
subsequently	subsequently	RB	I-VP	O
recommended	recommend	VBN	I-VP	O
for	for	IN	B-PP	O
Zanaflex	Zanaflex	NN	B-NP	O
therapy	therapy	NN	I-NP	O
which	which	WDT	B-NP	O
subsequently	subsequently	RB	B-ADVP	O
improved	improve	VBD	B-VP	O
her	her	PRP$	B-NP	O
pain	pain	NN	I-NP	O
control	control	NN	I-NP	O
dramatically	dramatically	RB	B-ADVP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
otherwise	otherwise	RB	B-ADVP	O
remained	remain	VBD	B-VP	O
intact	intact	JJ	B-ADJP	O
from	from	IN	B-PP	O
a	a	DT	B-NP	O
neurological	neurological	JJ	I-NP	O
perspective	perspective	NN	I-NP	O
for	for	IN	B-PP	O
the	the	DT	B-NP	O
duration	duration	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
stay	stay	NN	I-NP	O
,	,	,	O	O
demonstrating	demonstrate	VBG	B-VP	O
frequent	frequent	JJ	B-NP	O
emotional	emotional	JJ	I-NP	O
ability	ability	NN	I-NP	O
consistent	consistent	JJ	B-ADJP	O
with	with	IN	B-PP	O
her	her	PRP$	B-NP	O
baseline	baseline	NN	I-NP	O
examination	examination	NN	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Cardiovascular	Cardiovascular	JJ	B-ADJP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
remained	remain	VBD	B-VP	O
stable	stable	JJ	B-ADJP	O
from	from	IN	B-PP	O
a	a	DT	B-NP	O
cardiovascular	cardiovascular	JJ	I-NP	O
perspective	perspective	NN	I-NP	O
for	for	IN	B-PP	O
the	the	DT	B-NP	O
duration	duration	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
stay	stay	NN	I-NP	O
with	with	IN	B-PP	O
no	no	DT	B-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
acute	acute	JJ	B-NP	O
hemodynamic	hemodynamic	JJ	I-NP	O
instability	instability	NN	I-NP	O
or	or	CC	I-NP	O
compromise	compromise	NN	I-NP	O
.	.	.	O	O

At	At	IN	B-PP	O
no	no	DT	B-NP	O
point	point	NN	I-NP	O
did	do	VBD	B-VP	O
she	she	PRP	B-NP	O
demonstrate	demonstrate	VBP	B-VP	O
evidence	evidence	NN	B-NP	O
of	of	IN	B-PP	O
acute	acute	JJ	B-NP	O
myocardial	myocardial	JJ	I-NP	O
ischemia	ischemia	NN	I-NP	O
or	or	CC	I-NP	O
infarction	infarction	NN	I-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Pulmonary	Pulmonary	JJ	B-ADJP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
remained	remain	VBD	B-VP	O
stable	stable	JJ	B-ADJP	O
from	from	IN	B-PP	O
a	a	DT	B-NP	O
pulmonary	pulmonary	JJ	I-NP	O
perspective	perspective	NN	I-NP	O
for	for	IN	B-PP	O
the	the	DT	B-NP	O
duration	duration	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
stay	stay	NN	I-NP	O
with	with	IN	B-PP	O
no	no	DT	B-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
acute	acute	JJ	B-NP	O
respiratory	respiratory	JJ	I-NP	O
decompensation	decompensation	NN	I-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

GI	GI	LS	B-LST	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
remained	remain	VBD	B-VP	O
stable	stable	JJ	B-ADJP	O
from	from	IN	B-PP	O
a	a	DT	B-NP	O
gastrointestinal	gastrointestinal	JJ	I-NP	O
standpoint	standpoint	NN	I-NP	O
for	for	IN	B-PP	O
the	the	DT	B-NP	O
duration	duration	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
stay	stay	NN	I-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
tolerant	tolerant	JJ	B-ADJP	O
of	of	IN	B-PP	O
both	both	CC	B-NP	O
solid	solid	JJ	I-NP	O
and	and	CC	I-NP	O
liquid	liquid	JJ	I-NP	O
oral	oral	JJ	I-NP	O
intake	intake	NN	I-NP	O
.	.	.	O	O

Upon	Upon	IN	B-PP	O
discharge	discharge	NN	B-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
tolerant	tolerant	JJ	B-ADJP	O
of	of	IN	B-PP	O
both	both	CC	B-NP	O
solid	solid	JJ	I-NP	O
and	and	CC	I-NP	O
liquid	liquid	JJ	I-NP	O
p.o.	p.o.	NN	I-NP	O
intake	intake	NN	I-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
independently	independently	RB	B-ADJP	O
productive	productive	JJ	I-ADJP	O
of	of	IN	B-PP	O
adequate	adequate	JJ	B-NP	O
amounts	amount	NNS	I-NP	O
of	of	IN	B-PP	O
stool	stool	NN	B-NP	O
and	and	CC	I-NP	O
flatus	flatus	NN	I-NP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

GU	GU	NN	B-NP	O
:	:	:	O	O
As	As	IN	B-SBAR	O
described	describe	VBN	B-VP	O
previously	previously	RB	B-ADVP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
known	known	JJ	I-NP	O
diagnosis	diagnosis	NN	I-NP	O
of	of	IN	B-PP	O
a	a	DT	B-NP	O
urinary	urinary	JJ	I-NP	O
tract	tract	NN	I-NP	O
infection	infection	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
Macrobid	Macrobid	NNP	B-NP	O
therapy	therapy	NN	I-NP	O
through	through	IN	B-PP	O
9/8/2004	9/8/2004	CD	B-NP	O
,	,	,	O	O
at	at	IN	B-PP	O
which	which	WDT	B-NP	O
point	point	NN	I-NP	O
this	this	DT	B-NP	O
therapy	therapy	NN	I-NP	O
was	be	VBD	B-VP	O
discontinued	discontinue	VBN	I-VP	O
.	.	.	O	O

Subsequent	Subsequent	JJ	B-NP	O
follow-up	follow-up	NN	I-NP	O
urinalyses	uranalysis	NNS	I-NP	O
demonstrated	demonstrate	VBD	B-VP	O
no	no	DT	B-NP	O
further	further	JJ	I-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
urinary	urinary	JJ	B-NP	O
tract	tract	NN	I-NP	O
infection	infection	NN	I-NP	O
.	.	.	O	O

Upon	Upon	IN	B-PP	O
completion	completion	NN	B-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
Macrobid	Macrobid	JJ	I-NP	O
antibiotic	antibiotic	JJ	I-NP	O
course	course	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
Foley	Foley	NNP	I-NP	O
catheter	catheter	NN	I-NP	O
was	be	VBD	B-VP	O
removed	remove	VBN	I-VP	O
and	and	CC	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
independently	independently	RB	B-ADJP	O
productive	productive	JJ	I-ADJP	O
of	of	IN	B-PP	O
adequate	adequate	JJ	B-NP	O
amounts	amount	NNS	I-NP	O
of	of	IN	B-PP	O
urine	urine	NN	B-NP	O
for	for	IN	B-PP	O
the	the	DT	B-NP	O
duration	duration	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
stay	stay	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
at	at	IN	B-PP	O
no	no	DT	B-NP	O
point	point	NN	I-NP	O
demonstrated	demonstrate	VBD	B-VP	O
any	any	DT	B-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
acute	acute	JJ	B-NP	O
renal	renal	JJ	I-NP	O
compromise	compromise	NN	I-NP	O
or	or	CC	I-NP	O
electrolyte	electrolyte	NN	I-NP	O
imbalance	imbalance	NN	I-NP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

Heme	Heme	NN	B-NP	B-protein
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
remained	remain	VBD	B-VP	O
stable	stable	JJ	B-ADJP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
stable	stable	JJ	I-NP	O
hematocrit	hematocrit	NN	I-NP	O
for	for	IN	B-PP	O
the	the	DT	B-NP	O
duration	duration	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
stay	stay	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
Plavix	Plavix	NN	B-NP	O
therapy	therapy	NN	I-NP	O
following	follow	VBG	B-PP	O
her	her	PRP$	B-NP	O
angiogram	angiogram	NN	I-NP	O
,	,	,	O	O
on	on	IN	B-PP	O
which	which	WDT	B-NP	O
she	she	PRP	B-NP	O
remains	remain	VBZ	B-VP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
time	time	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
discharge	discharge	NN	I-NP	O
.	.	.	O	O

DVT	DVT	NN	B-NP	O
prophylaxis	prophylaxis	NN	I-NP	O
was	be	VBD	B-VP	O
provided	provide	VBN	I-VP	O
via	via	IN	B-PP	O
subcutaneous	subcutaneous	JJ	B-NP	O
heparin	heparin	NN	I-NP	O
for	for	IN	B-PP	O
the	the	DT	B-NP	O
duration	duration	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
stay	stay	NN	I-NP	O
.	.	.	O	O

7	7	CD	B-NP	O
.	.	.	O	O

ID	ID	NN	B-NP	O
:	:	:	O	O
As	As	IN	B-SBAR	O
stated	state	VBN	B-VP	O
above	above	RB	B-ADVP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
operative	operative	JJ	I-NP	B-cell_line
cultures	culture	NNS	I-NP	I-cell_line
were	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	B-VP	O
grow	grow	VB	I-VP	O
coag.-negative	coag.-negative	JJ	B-NP	O
staph	staph	NN	I-NP	O
,	,	,	O	O
sensitive	sensitive	JJ	B-ADJP	O
to	to	TO	B-PP	O
both	both	CC	O	O
vancomycin	vancomycin	NN	B-NP	O
and	and	CC	I-NP	O
Keflex	Keflex	NN	I-NP	O
.	.	.	O	O

For	For	IN	B-PP	O
the	the	DT	B-NP	O
majority	majority	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
stay	stay	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
remained	remain	VBD	B-VP	O
on	on	IN	B-PP	O
vancomycin	vancomycin	NN	B-NP	O
therapy	therapy	NN	I-NP	O
but	but	CC	O	O
was	be	VBD	B-VP	O
transitioned	transitione	VBN	I-VP	O
to	to	TO	B-PP	O
Keflex	Keflex	NNP	B-NP	O
on	on	IN	B-PP	O
1/11/2004	1/11/2004	CD	B-NP	O
,	,	,	O	O
on	on	IN	B-PP	O
which	which	WDT	B-NP	O
she	she	PRP	B-NP	O
remained	remain	VBD	B-VP	O
for	for	IN	B-PP	O
the	the	DT	B-NP	O
duration	duration	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
stay	stay	NN	I-NP	O
.	.	.	O	O

At	At	IN	B-PP	O
the	the	DT	B-NP	O
time	time	NN	I-NP	O
of	of	IN	B-PP	O
discharge	discharge	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
been	be	VBN	I-VP	O
instructed	instruct	VBN	I-VP	O
to	to	TO	I-VP	O
complete	complete	VB	I-VP	O
an	an	DT	B-NP	O
additional	additional	JJ	I-NP	O
10-day	10-day	JJ	I-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
Keflex	Keflex	NNP	B-NP	O
therapy	therapy	NN	I-NP	O
.	.	.	O	O

Of	Of	IN	B-PP	O
note	note	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
remained	remain	VBD	B-VP	O
afebrile	afebrile	JJ	B-ADJP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
stable	stable	JJ	I-NP	O
white	white	JJ	I-NP	O
count	count	NN	I-NP	O
for	for	IN	B-PP	O
the	the	DT	B-NP	O
duration	duration	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
stay	stay	NN	I-NP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
wound	wound	NN	I-NP	O
exam	exam	NN	I-NP	O
demonstrated	demonstrate	VBD	B-VP	O
no	no	DT	B-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
further	further	JJ	B-NP	O
infection	infection	NN	I-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
ulcer	ulcer	NN	I-NP	B-DNA
site	site	NN	I-NP	I-DNA
.	.	.	O	O

8	8	CD	B-NP	O
.	.	.	O	O

Endocrine	Endocrine	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
maintained	maintain	VBD	B-VP	O
adequately	adequately	RB	B-NP	O
well-controlled	well-controlled	JJ	I-NP	O
blood	blood	NN	I-NP	O
sugars	sugar	NNS	I-NP	O
for	for	IN	B-PP	O
the	the	DT	B-NP	O
duration	duration	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
stay	stay	NN	I-NP	O
with	with	IN	B-PP	O
no	no	DT	B-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
acute	acute	JJ	B-NP	O
endocrinological	endocrinological	JJ	I-NP	O
compromise	compromise	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
subsequently	subsequently	RB	I-VP	O
cleared	clear	VBN	I-VP	O
for	for	IN	B-PP	O
discharge	discharge	NN	B-NP	O
to	to	TO	B-PP	O
a	a	DT	B-NP	O
rehabilitation	rehabilitation	NN	I-NP	O
facility	facility	NN	I-NP	O
on	on	IN	B-PP	O
postoperative	postoperative	JJ	B-NP	O
days	day	NNS	I-NP	O
10	10	CD	I-NP	O
and	and	CC	I-NP	O
3	3	CD	I-NP	O
,	,	,	I-NP	O
7/11/2004	7/11/2004	CD	I-NP	O
,	,	,	O	O
with	with	IN	B-PP	O
instructions	instruction	NNS	B-NP	O
for	for	IN	B-PP	O
follow	follow	VBP	B-VP	O
up	up	RP	B-PRT	O
.	.	.	O	O

CONDITION	CONDITION	NN	B-NP	O
ON	ON	NN	I-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
:	:	:	O	O
Patient	Patient	NN	B-NP	O
is	be	VBZ	B-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
discharged	discharge	VBN	I-VP	O
to	to	TO	B-PP	O
a	a	DT	B-NP	O
rehabilitation	rehabilitation	NN	I-NP	O
facility	facility	NN	I-NP	O
with	with	IN	B-PP	O
instructions	instruction	NNS	B-NP	O
for	for	IN	B-PP	O
follow	follow	VBP	B-VP	O
up	up	RP	B-PRT	O
.	.	.	O	O

STATUS	STATUS	NN	B-NP	O
AT	AT	NN	I-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
:	:	:	O	O
Stable	Stable	JJ	B-ADJP	O
.	.	.	O	O

DISCHARGE	DISCHARGE	NN	B-NP	O
DIAGNOSIS	DIAGNOSIS	NN	I-NP	O
:	:	:	O	O
Nonhealing	Nonheale	VBG	B-VP	O
right	right	JJ	B-NP	O
foot	foot	NN	I-NP	O
ulcer	ulcer	NN	I-NP	O
status	status	NN	I-NP	O
post	post	NN	I-NP	O
debridement	debridement	NN	I-NP	O
and	and	CC	O	O
closure	closure	NN	B-NP	O
with	with	IN	B-PP	O
an	an	DT	B-NP	O
angiogram	angiogram	NN	I-NP	O
and	and	CC	I-NP	O
angioplasty	angioplasty	NN	I-NP	O
.	.	.	O	O

CVA	CVA	NN	B-NP	B-protein
,	,	,	O	O
seizure	seizure	NN	B-NP	O
disorder	disorder	NN	I-NP	O
,	,	,	O	O
depression	depression	NN	B-NP	O
,	,	,	O	O
hypothyroidism	hypothyroidism	NN	B-NP	O
,	,	,	O	O
anemia	anemia	NN	B-NP	O
of	of	IN	B-PP	O
chronic	chronic	JJ	B-NP	O
disease	disease	NN	I-NP	O
,	,	,	O	O
SLE	SLE	NN	B-NP	O
,	,	,	O	O
interstitial	interstitial	JJ	B-NP	O
lung	lung	NN	I-NP	O
disease	disease	NN	I-NP	O
,	,	,	O	O
hypertension	hypertension	NN	B-NP	O
,	,	,	O	O
migraines	migraine	NNS	B-NP	O
,	,	,	O	O
subdural	subdural	JJ	B-NP	O
hematoma	hematoma	NN	I-NP	O
status	status	NN	I-NP	O
post	post	NN	I-NP	O
fall	fall	NN	I-NP	O
,	,	,	O	O
hypercholesterolemia	hypercholesterolemia	NN	B-NP	O
,	,	,	O	O
status	status	NN	B-NP	O
post	post	NN	I-NP	O
right	right	JJ	I-NP	O
CEA	CEA	NN	I-NP	O
,	,	,	O	O
craniotomy	craniotomy	NN	B-NP	O
and	and	CC	O	O
coronary	coronary	JJ	B-NP	O
stenting	stenting	NN	I-NP	O
.	.	.	O	O

DISCHARGE	DISCHARGE	NN	B-NP	O
MEDICATIONS	MEDICATIONS	NNS	I-NP	O
:	:	:	O	O
Tylenol	Tylenol	NN	B-NP	O
650	650	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.	q.	NN	I-NP	O
4h	4h	NN	I-NP	O
.	.	.	O	O

p.r.n.	p.r.n.	LS	B-LST	O
,	,	,	O	O
aspirin	aspirin	NN	B-NP	O
325	325	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.day	q.day	NN	I-NP	O
,	,	,	O	O
Dulcolax	Dulcolax	NN	B-NP	O
10	10	CD	I-NP	O
mg	mg	NN	I-NP	O
PR	PR	NN	I-NP	O
q.day	q.day	NN	I-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
,	,	,	O	O
Colace	Colace	NNP	B-NP	O
100	100	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
b.i.d.	b.i.d.	FW	I-ADVP	O
,	,	,	O	O
Epogen	Epogen	NN	B-NP	B-protein
40	40	CD	I-NP	I-protein
,	,	,	I-NP	O
000	000	CD	I-NP	O
units	unit	NNS	I-NP	O
SC	SC	NN	I-NP	O
q.week	q.week	NN	I-NP	O
,	,	,	O	O
iron	iron	NN	B-NP	O
325	325	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
b.i.d.	b.i.d.	FW	I-ADVP	O
,	,	,	O	O
folate	folate	VB	B-VP	O
1	1	CD	B-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.day	q.day	NN	I-NP	O
,	,	,	O	O
heparin	heparin	NN	B-NP	O
5000	5000	CD	B-NP	O
units	unit	NNS	I-NP	O
SC	SC	NNP	B-NP	O
b.i.d.	b.i.d.	NNP	I-NP	O
,	,	,	O	O
Dilaudid	Dilaudid	VBD	B-VP	O
0.5-1	0.5-1	CD	B-NP	O
mg	mg	NN	I-NP	O
IV	IV	CD	B-NP	O
q.	q.	NN	I-NP	O
4h	4h	NN	I-NP	O
.	.	.	O	O

p.r.n.	p.r.n.	NN	B-NP	O
for	for	IN	B-PP	O
pain	pain	NN	B-NP	O
,	,	,	O	O
Dilaudid	Dilaudid	VBD	B-VP	O
4-8	4-8	CD	B-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.	q.	NN	I-NP	O
3h	3h	NN	I-NP	O
.	.	.	O	O

p.r.n.	p.r.n.	NN	B-NP	O
for	for	IN	B-PP	O
pain	pain	NN	B-NP	O
,	,	,	O	O
Plaquenil	Plaquenil	NN	B-NP	O
200	200	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.day	q.day	NN	I-NP	O
,	,	,	O	O
Levoxyl	Levoxyl	NN	B-NP	O
200	200	CD	I-NP	O
mcg	mcg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.day	q.day	NN	I-NP	O
,	,	,	O	O
lisinopril	lisinopril	NN	B-NP	O
10	10	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.day	q.day	NN	I-NP	O
,	,	,	O	O
Ativan	Ativan	NNP	B-NP	O
1	1	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.h.s.	q.h.s.	NN	I-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
,	,	,	O	O
milk	milk	NN	B-NP	O
of	of	IN	B-PP	O
magnesia	magnesia	NN	B-NP	O
30	30	CD	I-NP	O
ml	ml	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.day	q.day	NN	I-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
,	,	,	O	O
Reglan	Reglan	NN	B-NP	O
10	10	CD	I-NP	O
mg	mg	NN	I-NP	O
IV	IV	CD	B-NP	O
q.	q.	NN	I-NP	O
6h	6h	NN	I-NP	O
.	.	.	O	O

p.r.n.	p.r.n.	LS	B-LST	O
,	,	,	O	O
nicotine	nicotine	NN	B-NP	O
10	10	CD	I-NP	O
mg	mg	NN	I-NP	O
per	per	IN	B-PP	O
day	day	NN	B-NP	O
topical	topical	JJ	B-NP	O
patch	patch	NN	I-NP	O
q.	q.	NN	I-NP	O
24h	24h	NN	I-NP	O
.	.	.	O	O

,	,	,	O	O
Dilantin	Dilantin	NN	B-NP	O
200	200	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
,	,	,	O	O
senna	senna	NN	B-NP	O
tablets	tablet	NNS	I-NP	O
1-2	1-2	CD	B-NP	O
tablets	tablet	NNS	I-NP	O
p.o.	p.o.	FW	I-NP	O
b.i.d.	b.i.d.	FW	I-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
,	,	,	O	O
multivitamin	multivitamin	NN	B-NP	O
1	1	CD	I-NP	O
tab	tab	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.day	q.day	NN	I-NP	O
,	,	,	O	O
Keflex	Keflex	NNP	B-NP	O
500	500	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.i.d.	q.i.d.	FW	I-NP	O
x	x	SYM	I-NP	O
40	40	CD	I-NP	O
doses	dose	NNS	I-NP	O
,	,	,	O	O
Toprol-XL	Toprol-XL	NN	B-NP	O
50	50	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.day	q.day	NN	I-NP	O
,	,	,	O	O
Neurontin	Neurontin	NN	B-NP	B-protein
300	300	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
p.o.	p.o.	FW	I-NP	I-protein
q.h.s.	q.h.s.	NN	I-NP	I-protein
,	,	,	O	O
Ultram	Ultram	NNP	B-NP	O
25	25	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.	q.	NN	I-NP	O
8h	8h	NN	I-NP	O
.	.	.	O	O

p.r.n.	p.r.n.	LS	B-LST	O
,	,	,	O	O
OxyContin	OxyContin	NNP	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.	q.	NN	I-NP	O
12h	12h	NN	I-NP	O
.	.	.	O	O

,	,	,	O	O
Zyprexa	Zyprexa	NNP	B-NP	O
5	5	CD	I-NP	O
mg	mg	NN	I-NP	O
SL	SL	NN	I-NP	O
q.h.s.	q.h.s.	NN	I-NP	O
,	,	,	O	O
Plavix	Plavix	NNP	B-NP	O
75	75	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.day	q.day	NN	I-NP	O
,	,	,	O	O
Celexa	Celexa	NNP	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.day	q.day	NN	I-NP	O
,	,	,	O	O
Zanflex	Zanflex	NN	B-NP	B-protein
4	4	CD	I-NP	I-protein
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
t.i.d.	t.i.d.	FW	I-ADVP	O
,	,	,	O	O
Advair	Advair	NNP	B-NP	O
Diskus	Diskus	NNP	I-NP	O
500/50	500/50	CD	I-NP	O
1	1	CD	I-NP	O
puff	puff	NN	I-NP	O
inhaled	inhale	VBD	B-VP	O
b.i.d.	b.i.d.	RB	B-ADVP	O
,	,	,	O	O
DuoNeb	DuoNeb	NNP	B-NP	O
3/0	3/0	CD	I-NP	O
.5	.5	CD	I-NP	O
mg	mg	NN	I-NP	O
inhaled	inhale	VBD	B-VP	O
q.	q.	NN	B-NP	O
6h	6h	NN	I-NP	O
.	.	.	O	O

p.r.n.	p.r.n.	LS	B-LST	O
,	,	,	O	O
Maalox	Maalox	NNP	B-NP	O
1-2	1-2	CD	I-NP	O
tablets	tablet	NNS	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.	q.	FW	I-NP	O
6h	6h	NN	I-NP	O
.	.	.	O	O

p.r.n.	p.r.n.	LS	B-LST	O
for	for	IN	B-PP	O
upset	upset	JJ	B-NP	O
stomach	stomach	NN	I-NP	O
.	.	.	O	O

DISCHARGE	DISCHARGE	NN	B-NP	O
INSTRUCTIONS	INSTRUCTIONS	NNS	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Patient	Patient	NN	B-NP	O
is	be	VBZ	B-VP	O
to	to	TO	B-VP	O
maintain	maintain	VB	I-VP	O
her	her	PRP$	B-NP	O
incision	incision	NN	I-NP	O
sites	site	NNS	I-NP	O
clean	clean	JJ	B-ADJP	O
and	and	CC	O	O
dry	dry	JJ	B-ADJP	O
at	at	IN	B-PP	O
all	all	DT	B-NP	O
times	time	NNS	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
may	may	MD	B-VP	O
shower	shower	VB	I-VP	O
but	but	CC	O	O
should	should	MD	B-VP	O
pat	pat	VB	I-VP	O
dry	dry	JJ	B-ADJP	O
her	her	PRP$	B-NP	O
incisions	incision	NNS	I-NP	O
afterwards	afterwards	RB	B-ADVP	O
;	;	:	O	O
no	no	DT	B-NP	O
bathing	bathing	NN	I-NP	O
or	or	CC	I-NP	O
swimming	swimming	NN	I-NP	O
until	until	IN	B-SBAR	O
further	further	JJ	B-NP	O
notice	notice	NN	I-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

No	No	DT	B-NP	O
driving	driving	NN	I-NP	O
while	while	IN	B-SBAR	O
taking	take	VBG	B-VP	O
prescription	prescription	NN	B-NP	O
narcotic	narcotic	JJ	I-NP	O
medications	medication	NNS	I-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Patient	Patient	NN	B-NP	O
may	may	MD	B-VP	O
resume	resume	VB	I-VP	O
a	a	DT	B-NP	O
regular	regular	JJ	I-NP	O
diet	diet	NN	I-NP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Patient	Patient	NN	B-NP	O
is	be	VBZ	B-VP	O
to	to	TO	B-VP	O
limit	limit	VB	I-VP	O
physical	physical	JJ	B-NP	O
exercise	exercise	NN	I-NP	O
;	;	:	O	O
no	no	DT	B-NP	O
heavy	heavy	JJ	I-NP	O
exertion	exertion	NN	I-NP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

Patient	Patient	NN	B-NP	O
is	be	VBZ	B-VP	O
to	to	TO	B-VP	O
follow	follow	VB	I-VP	O
up	up	RP	B-PRT	O
with	with	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Garrett	Garrett	NNP	I-NP	O
Buckner	Buckner	NNP	I-NP	O
within	within	IN	B-PP	O
7-10	7-10	CD	B-NP	O
days	day	NNS	I-NP	O
;	;	:	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
to	to	TO	B-VP	O
call	call	VB	I-VP	O
to	to	TO	B-VP	O
schedule	schedule	VB	I-VP	O
an	an	DT	B-NP	O
appointment	appointment	NN	I-NP	O
.	.	.	O	O

eScription	eScription	NN	B-NP	O
document	document	NN	I-NP	O
:	:	:	O	O
5-7381260	5-7381260	CD	B-NP	O
LMSSten	LMSSten	NNP	I-NP	O
Tel	Tel	NNP	I-NP	O
Dictated	Dictated	NNP	I-NP	O
By	By	NNP	I-NP	O
:	:	:	O	O
CASSIDY	CASSIDY	NN	B-NP	O
,	,	,	O	O
HUNTER	HUNTER	NNP	B-NP	O
Attending	Attending	NNP	I-NP	O
:	:	:	O	O
BARENTINE	BARENTINE	NNP	B-NP	O
,	,	,	O	O
ERNESTO	ERNESTO	NNP	B-NP	O
VICTOR	VICTOR	NNP	I-NP	O
Dictation	Dictation	NNP	I-NP	O
ID	ID	NNP	I-NP	O
8010716	8010716	CD	I-NP	O
D	D	NNP	I-NP	O
:	:	:	O	O
11/11/04	11/11/04	CD	B-NP	O
T	T	NN	I-NP	O
:	:	:	O	O
11/11/04	11/11/04	CD	B-NP	O

